




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 231/44, A61K 31/415, 31/47, C07D 401/06, 231/38, 231/52, 403/06	A1	(11) International Publication Number: WO 94/13644 (43) International Publication Date: 23 June 1994 (23.06.94)
(21) International Application Number: PCT/US93/10716 (22) International Filing Date: 12 November 1993 (12.11.93) (30) Priority Data: 07/991,763 17 December 1992 (17.12.92) US (60) Parent Application or Grant (63) Related by Continuation US 07/991,763 (CIP) Filed on 17 December 1992 (17.12.92) (71) Applicant (for all designated States except US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): BRIGHT, Gene, Michael [US/US]; 329 Tyler Avenue, Groton, CT 06340 (US). (74) Agents: RICHARDSON, Peter, C. et al.; Pfizer Inc., Patent Dept., 235 East 42nd Street, New York, NY 10017 (US).		(81) Designated States: AU, BR, CA, CZ, JP, KR, NO, NZ, PL, RU, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: AMINO-SUBSTITUTED PYRAZOLES HAVING CRF ANTAGONISTIC ACTIVITY <div style="text-align: center;">  <p style="text-align: right;">(I)</p> </div> (57) Abstract <p>Substituted pyrazoles of formula (I), wherein R₁, R₂, R₃, X, Y, Z and A are as defined herein, have corticotropin-releasing factor (CRF) antagonist activity. As such, they are effective in the treatment of a wide range of diseases including stress-related illnesses.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

Amino-substituted pyrazoles having CRF antagonistic activity.


5

This invention relates to substituted pyrazoles, pharmaceutical compositions containing them, and their use in the treatment of stress-related and other diseases. The compounds have corticotropin-releasing factor (CRF) antagonist activity.

CRF antagonists are mentioned in U.S. Patents 4,605,642 and 5,063,245 referring to peptides and pyrazolinones, respectively. The importance of CRF antagonists is set out in the literature, e. g. as discussed in U.S. Patent 5,063,245, which is incorporated herein by reference. A recent outline of the different activities possessed by CRF antagonists is found in M. J. Owens et al., Pharm. Rev., Vol. 43, pages 425 to 473 (1991), also incorporated herein by reference. Based on the research described in these two and other references, CRF antagonists are considered effective in the treatment of a wide range of diseases including stress-related illnesses, such as stress-induced depression, anxiety, and headache; abdominal bowel syndrome, inflammatory diseases; immune suppression; human immunodeficiency virus (HIV) infections; Alzheimer's disease; gastrointestinal diseases; anorexia nervosa; hemorrhagic stress; drug and alcohol withdrawal symptoms; drug addiction, and fertility problems.

The present invention relates to a compound of the formula

25



30 and the pharmaceutically acceptable acid addition salts thereof, wherein

A is CH₂;

X₁ is a covalent bond, CH₂, O, S, or NR, wherein R is hydrogen, linear C₁-C₆ alkyl, or branched C₃-C₈ alkyl;

35 R₁, R₂ and R₃ are each independently linear C₁-C₆ alkyl, branched C₃-C₈ alkyl, C₃-C₈ alkenyl wherein the double bond is not adjacent to the N or X₁ when X₁ is oxygen or sulfur, or C₃-C₇ cycloalkyl (CH₂)_n wherein n is 0, 1, 2, 3 or 4; or R₁ and R₂ when


-2-

taken together with the nitrogen form a saturated four, five or six membered ring optionally condensed with benzo; and R_3 may also be $(CH_2)_q Q_1 R_{19}$ wherein q is 0, 1 or 2, Q_1 is O, S, NH, $N(C_1-C_6 \text{ alkyl})$ or a covalent bond when X_1 is not a covalent bond, and R_{19} is hydrogen, linear C_1-C_6 alkyl, branched C_3-C_8 , C_3-C_8 alkenyl, or C_3-C_8 cycloalkyl $(CH_2)_n$ wherein n is 0 to 4;

Y is phenyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, benzimidazolyl, furanyl, benzofuranyl, thiazolyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, isoxazolyl, benzisoxazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, oxazolyl, benzoxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, or piperidinyl, each of which may be substituted by one to three of any one of fluoro, chloro, bromo, or methyl, or one of trifluoromethyl; with the proviso that Y is not unsubstituted phenyl; and

Z is

(a)



wherein the B ring is phenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, thienyl, or indolyl, each of which may be substituted by methyl, methoxy, fluoro, chloro, bromo or iodo; or a saturated 5- or 6-membered carbocyclic ring or a partially unsaturated ring having one or two double bonds;

R_4 is hydrogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, hydroxy, fluoro, chloro, bromo, iodo, or trifluoromethyl;

R_5 is hydrogen, linear C_1-C_6 alkyl, branched C_3-C_8 alkyl, C_3-C_8 alkenyl, or $(CH_2)_o-X_2-(CH_2)_r-Q_2-R_6$;

R_6 is hydrogen, linear C_1-C_6 alkyl, branched C_3-C_8 alkyl, or C_3-C_8 alkenyl;

-3-

X_2 and Q_2 are each independently O, S, NH, N(C₁-C₆ alkyl), or one of X_2 and Q_2 may be a covalent bond;

m is 0 or 1;


o is 1 or 2;

5 p is 1 or 2; and

r is 0, 1, or 2;

(b)

10




wherein R_4 and R_5 are as defined above, and t and u are each independently 1 or 2;

15 (c) $-NR_7R_8$ wherein R_7 and R_8 are each independently hydrogen, C₁-C₆ linear alkyl, branched C₃-C₈ alkyl, C₃-C₈ alkenyl, $(CH_2)_vCH_2OH$, $(CH_2)_vNR_9R_{10}$, wherein v is 0 to 3, and R_9 and R_{10} are each independently hydrogen, or linear C₁-C₆ alkyl; C₁-C₁₂ cycloalkyl, (C₃-C₁₂ cycloalkyl) $(CH_2)_n$, (C₆-C₁₀ bicycloalkyl) $(CH_2)_n$, wherein n is 0 to 4, benzofused C₃-C₆ cycloalkyl, C₁-C₆ hydroxyalkyl, phenyl, phenyl (C₁-C₃ alkylene), each
20 of which may be substituted by one or two of hydroxy, fluoro, chloro, bromo, C₁-C₅ alkyl, or C₁-C₅ alkoxy; or R_7 and R_8 may be taken together with the nitrogen to form a saturated or partially unsaturated 5- to 7-membered ring which may contain one of O, S, NH or N(C₁-C₆ alkyl) and which may be substituted by C₁-C₆ alkyl, hydroxy or phenyl wherein any double bond(s) are not adjacent to any heteroatoms;

25 (d)


30



-4-


wherein B, R₄ and R₅ are as defined above, w, x, y and z are each independently 1 or 2, and W is (CH₂)_q wherein q is as defined above, N(C₁-C₈ alkyl), or oxygen;

(e)



wherein B, R₄, m and p are as defined above;

(f)



wherein B and R₄ are as defined above;


(g) O(CH₂)_vR₁₁

wherein v is 0 to 3 and R₁₁ is linear C₁-C₈ alkyl, branched C₃-C₈ alkyl, phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, benzimidazolyl, furanyl, benzofuranyl, thiazolyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, isoxazolyl, benzisoxazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, oxazolyl, benzoxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, piperidinyl, or thienyl, each of which may be substituted by one or two of any one of fluoro, chloro, bromo, methyl, or trifluoromethyl;

30

-5-

(h)




5

wherein A is defined above and is linked to position 1 or 2 while R_{14} is attached to position 2 or 1, respectively; F, G, H, I, J and K are independently C or N, provided that not more than three of H, I, J and K are N with not more than two adjacent nitrogens;

- 10 R_{12} and R_{13} each independently are hydrogen, linear C_1 - C_8 alkyl, branched C_3 - C_8 alkyl, C_3 - C_8 alkenyl, fluoro, chloro, bromo, trifluoromethyl, hydroxy, thiol, C_1 - C_{12} alkoxy, C_1 - C_{12} thioalkanyl, or C_3 - C_{12} alkenoxy or C_3 - C_{12} thioalkenyl wherein the double bond is not adjacent to the oxygen or sulfur, and R_{14} is hydroxy, C_1 - C_{12} alkoxy, C_3 - C_{12} alkenoxy wherein the double bond is not adjacent to the oxygen, or $-X_2-(CH_2)_nQ_2R_6$ wherein X_2 ,
 15 r , Q_2 and R_6 are as defined above in paragraph (a) except that Q is not sulfur, or R_{14} is $NR_{15}R_{16}$ wherein R_{15} and R_{16} are each independently hydrogen, linear C_1 - C_8 alkyl, branched C_3 - C_8 alkyl, C_3 - C_8 alkenyl wherein the double bond is not adjacent to the nitrogen, or C_3 - C_7 cycloalkyl- $(CH_2)_n$ wherein n is as defined above, or R_{15} and R_{16} together with the nitrogen form a saturated five or six membered ring optionally
 20 condensed with benzo; or

(i)



25

- wherein D, E, F and G are independently C or N, provided that not more than two of D, E, F and G are N, and R_{12} and R_{14} are as defined in paragraph (h), A, defined above, is linked to a carbon in formula XV, and R_{14} is linked to a carbon located adjacent to
 30 the carbon to which A is linked.

More specific compounds of formula I of the invention include those wherein Y is phenyl substituted by three substituents one each at positions 2, 4 and 6, e.g. 2,4,6-trichlorophenyl, 2,6-dichloro-4-trifluoromethylphenyl, or 2,6-dichloro-4-fluorophenyl.

-6-

Other more specific compounds of formula I include those wherein XR_3 is ethyl or methylthio, those wherein R_1 and R_2 are each methyl, and those wherein Z is NR_7R_8 and R_7 is phenyl or phenyl substituted by one of fluoro, chloro, nitro, methyl or methoxy and R_8 is as defined above, preferably, $(CH_2)_3OH$, CH_2CH_2OH or methyl.


- 5 Preferred compounds of formula I are those wherein Z is 1,2,3,4-tetrahydroisoquinolin-2-yl substituted by R_5 which is $-(CH_2)_6-X_2-(CH_2)_7-Q_2-R_6$, more specifically R_5 is $-(CH_2)_kOH$ wherein k is an integer of 1 to 4, or $-CH_2OCH_2CH_2OR_6$. Other preferred compounds of formula I are those wherein Z is 1,2,3,4-tetrahydroquinolin-2-yl wherein R_5 is substituted at position 3, and the absolute
10 configuration at the 3 position is either S or R or R,S.

Preferred compounds of the formula I include those wherein Z is as defined in above subparagraph (h); and those wherein Z is as defined in (h), A is linked to position 1, F, G, H, I, J and K are each carbon, and R_{14} is methoxy, ethoxy, isopropoxy, or cyclopropylmethoxy at position 2.

- 15 Other preferred compounds of formula I are those wherein Z is as defined in above subparagraph (h), A is linked to position 1, K is nitrogen, F, G, H, I, and J are each carbon, and R_{14} is $-X_2-(CH_2)_7-Q_2R_6$ at position 2; those wherein Z is as defined in (h), A is linked to position 1, K is nitrogen, F, G, H, I, and J are each carbon, and R_{14} is methoxy, ethoxy, isopropoxy, or cyclopropylmethoxy at position 2; and those wherein
20 Z is as defined in (h), A is at position 1, and R_{14} is ethoxy, isopropoxy or cyclopropylmethoxy at position 2. In these preferred compounds of formula I wherein Z is as defined in (h), R_{12} and R_{13} are preferably hydrogen.

Other preferred compounds of formula I are those wherein Z is as defined in subparagraph (a), B is phenyl, p and m are each 1, and R_5 is CH_2OCH_3 .

- 25 Preferred compounds of formula I include those wherein Z is



30

wherein B is phenyl, m is 0, and p is 1.

Specific most preferred compounds of the invention include:

2-{1-[1-(2,6-dichloro-4-trifluoromethylphenyl)-5-dimethylamino-3-ethyl-1H-pyrazol-4-ylmethyl]-naphthalen-2-yloxy}-ethanol;

5 enantiomeric [4-(3-methoxymethyl-3,4-dihydro-1H-isoquinolin-2-ylmethyl)-5-methylsulfanyl-2-(2,4,6-trichlorophenyl)-2H-pyrazol-3-yl]-dimethylamine derived from (+)-3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline;

enantiomeric [2-(2,6-dichloro-4-trifluoromethylphenyl)-4-(3-ethoxymethyl-3,4-dihydro-1H-isoquinolin-2-ylmethyl)-5-ethyl-2H-pyrazol-3-yl]-dimethylamine derived from
10 (+)-3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline;

[2-(2,6-dichloro-4-trifluoromethylphenyl)-5-ethyl-4-(7-methoxyquinolin-8-ylmethyl)-2H-pyrazol-3-yl]-dimethylamine;

[2-(2,6-dichloro-4-trifluoromethylphenyl)-4-(2-ethoxy-naphthalen-1-ylmethyl)-5-ethyl-2H-pyrazol-3-yl]-dimethylamine;

15 [4-(2-ethoxynaphthalen-1-ylmethyl)-5-ethyl-2-(2,4,6-trichlorophenyl)-2H-pyrazol-3-yl]-dimethylamine;

[4-(7-methoxyquinolin-8-ylmethyl)-5-methylsulfanyl-2-(2,4,6-trichlorophenyl)-2H-pyrazol-3-yl]-dimethylamine;

20 2-{1-[5-dimethylamino-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-ylmethyl]-naphthalen-2-yloxy}-ethanol;

enantiomeric [2-(2,6-dichloro-4-trifluoromethylphenyl)-5-ethyl-4-(3-methoxymethyl-3,4-dihydro-1H-isoquinolin-2-ylmethyl)-2H-pyrazol-3-yl]-dimethylamine derived from (+)-3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline;

[4-(2-cyclopropylmethoxynaphthalen-1-ylmethyl)-5-methylsulfanyl-2-(2,4,6-trichlorophenyl)-2H-pyrazol-3-yl]-dimethylamine;

25 2-{[5-dimethylamino-3-ethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazol-4-ylmethyl]-naphthalen-2-yloxy}-ethanol;

2-{1-[5-dimethylamino-3-methylsulfanyl-1-(2,4,6-trimethylphenyl)-1H-pyrazol-4-ylmethyl]-naphthalen-2-yloxy}-ethanol;

30 [2-(2,6-dichloro-4-trifluoromethylphenyl)-5-methoxymethyl-4-(2-methoxy-naphthalen-1-ylmethyl)-2H-pyrazol-3-yl]-dimethylamine;

2-{1-[5-dimethylamino-3-ethyl-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-ylmethyl]-naphthalen-2-yloxy}-ethanol;

[5-ethyl-4-(2-methoxy-naphthalen-1-ylmethyl)-2-(2,4,6-trimethylphenyl)-2H-pyrazol-3-yl]-dimethylamine;

2-{2-[1-(2,6-dichloro-4-trifluoromethylphenyl)-5-dimethylamino-3-ethyl-1H-pyrazol-4-ylmethyl]-1,2,3,4-tetrahydroisoquinolin-3-ylmethoxy}-ethanol;

5 [4-(3-methoxymethyl-3,4-dihydro-1H-isoquinolin-2-ylmethyl)-5-methylsulfanyl-2-(2,4,6-trimethylphenyl)-2H-pyrazol-3-yl]-dimethylamine; and

2-{2-[5-dimethylamino-3-ethyl-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-ylmethyl]-1,2,3,4-tetrahydroisoquinolin-3-ylmethoxy}-ethanol.


The invention also relates to a compound of the formula 1A (not shown) and the
10 pharmaceutically acceptable acid addition salts thereof. The compounds of the formula 1A are identical to those of the formula I except that A is $\text{CH}(\text{C}_1\text{-C}_6 \text{ alkyl})$, $\text{C}(\text{C}_1\text{-C}_6 \text{ alkyl})_2$, $\text{C}(\text{C}_1\text{-C}_6 \text{ alkyl})(\text{C}_3\text{-C}_8 \text{ alkenyl})$, $\text{CH}(\text{CH}_2)_n(\text{C}_3\text{-C}_8 \text{ alkenyl})$ wherein n is 0 to 4 or $\text{C}(\text{C}_3\text{-C}_8 \text{ alkenyl})_2$.

The invention includes a pharmaceutical composition for the treatment of
15 illnesses induced or facilitated by corticotropin releasing factor which comprises a compound of the formula I or IA as defined above in an amount effective in the treatment of said illnesses, and a pharmaceutically acceptable carrier, and a composition for the treatment of inflammatory disorders, stress and anxiety related disorders including stress-induced depression and headache, abdominal bowel
20 syndrome, immune suppression, HIV infections, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, hemorrhagic stress, drug and alcohol withdrawal symptoms, drug addiction, and fertility problems, which comprises a compound of the formula I or IA as defined above in an amount effective in the treatment of said disorders, and a pharmaceutically acceptable carrier. Preferred and more specific compositions of the
25 invention are those containing preferred and more specific compounds of formula I as described above.

The invention further relates to a method for the treatment of illnesses induced or facilitated by corticotropin releasing factor by administering to a subject in need of such treatment a compound of formula I or IA as defined above, and a method for the
30 treatment of stress and anxiety related disorders including stress-induced depression and headache, abdominal bowel syndrome, inflammatory disorders, immune suppression HIV infections Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, hemorrhagic stress, drug and alcohol withdrawal symptoms, drug addiction,

and fertility problems, particularly depression, by administering to a subject in need of such treatment a compound of formula I or 1A as defined above. Preferred and more specific methods of the invention are those administering preferred and more specific compound of the formula I as described above.

5 The invention also relates to an intermediate compound of the formula



10

wherein R' is CH₂OH or C(O)O(C₁-C₃ alkyl), R₁, R₂ and R₃ are each independently linear C₁-C₆ alkyl, branched C₃-C₈ alkyl, C₃-C₈ alkenyl wherein the double bond is not
 15 adjacent to the N or X₁ when X₁ is oxygen or sulfur, C₃-C₇ cycloalkyl (CH₂)_n wherein n is 0, 1, 2, 3 or 4; or R₁ and R₂ when taken together with the nitrogen form a saturated four, five or six membered ring optionally condensed with benzo;

X₁ is a covalent bond, CH₂NR wherein R is hydrogen or linear C₁-C₆ alkyl, O, or S; and

20 Y is phenyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, benzimidazolyl, furanyl, benzofuranyl, thiazolyl, benzothiazolyl, isothiazolyl, benzoisothiazolyl, isoxazolyl, benzisoxazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, oxazolyl, benzoxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, or piperidinyl, each of which may be substituted by one to three of any one of fluoro, chloro, bromo,
 25 or methyl, or one of trifluoromethyl; with the proviso that Y is not unsubstituted phenyl.


Whenever reference herein is made to groups (CH₂)_qR₁₉ and (CH₂)_o-X₂-CH₂)_r-Q₂-R₆, then X₁ and Q₁, and X₂ and Q₂, respectively, are not both a heteroatom when q or r, respectively, is 1.

30 Whenever Y or R₁₁ is a heterocyclic group, the attachment of the group is through a carbon atom.

The compounds of formula I may be prepared by reaction of a compound of the formula

-10-


5



with a sulfonyl chloride such as methylsulfonylchloride, in a solvent such as methylene
 10 chloride or toluene, at temperatures of about -10 to about 30°C, followed by reaction
 with a compound of the formula ZH or ZMetal wherein Z is as defined above and Metal
 is an alkali metal such as sodium, lithium or potassium. The reaction with ZH proceeds
 generally in the presence of a solvent such as methylene chloride or toluene at
 temperatures of about 50 to about 100°C in the presence of a strong base such as an
 15 alkali metal hydride, e.g. sodium hydride, lithium hydride or potassium hydride, except
 when ZH is a sufficiently strong base itself, in which case a stoichiometric excess of ZH
 may be used or a stoichiometric amount of ZH in the presence of a suitably strong
 base such as a trialkylamine, e.g. triethylamine. The reaction with ZMetal proceeds in
 solvents such as N,N-dimethylformamide at temperatures in the range of about 50 to
 20 about 100°C.

The compounds of formula VIII may be prepared by reacting a compound of the
 formula

25




30 wherein X₁, Y, R₁, R₂ and R₃ are as defined with reference to formula I, except that R₁
 and R₂ are not hydrogen, with a reducing agent which is compatible with the chemical
 substituents on the aminopyrazole ring, such as diisobutylaluminum hydride in a


reaction inert solvent such as tetrahydrofuran or ether, at temperatures of about -5 to 30°C.

The compounds of the formula IX may be prepared from the corresponding compounds wherein R₁ and R₂ are hydrogen (formula X, not shown) by reacting first
 5 with an alkali metal hydride such as sodium hydride and then with alkylating agents R₁Hal and R₂Hal wherein Hal is chloro or bromo and R₁ and R₂ are as defined with reference to formula I except hydrogen, in a solvent such as tetrahydrofuran at temperatures of about 5 to 80°C.


The compounds of the formula X may be prepared by reacting a 2-cyano-acrylic
 10 acid ester of the formulae



to make a compound of the formula I wherein X₁ is S,




to make a compound of formula I wherein X₁ is a covalent bond,



to make a compound of formula I wherein X₁ is O, or

-12-


5



to make a compound of formula I wherein X_1 is NR and R is hydrogen, wherein R_{17} is C_1 - C_3 alkyl and R_{18} is C_1 - C_2 alkyl, with a hydrazine of the formula NH_2NHY wherein Y is as defined with reference to formula I. The reaction is carried out in a solvent, such as a C_1 - C_8 alcohol, at about 50 to 150°C, conveniently the reflux temperature of the reaction mixture. The wavy line \sim in some of the formulae herein indicates that either isomer of this compound is included, in accordance with accepted convention for indicating stereoisomers.

The intermediates of formula IX obtained by the above reaction from the compound of formula XIV have the formula

20




They may be trialkylated by using at least three equivalents of alkali metal hydride and R_2Hal wherein Hal is chloro or bromo, in the manner described above for conversion of the compounds of formula X to the compounds of formula IX, to obtain the compounds of formula I wherein R_1 , R_2 and R are as defined above with reference to formula I other than hydrogen.

The above intermediates of the formula IXA may be reacted with a compound providing an N-protecting group to replace the hydrogen in the NHR_3 group followed by alkylation with R_2Hal or R_3Hal and removal of the N-protecting group to provide the compounds of the formula I wherein X_1 is NRR_3 wherein R is hydrogen, and R_2 and R_3 are as defined above with reference to formula I other than hydrogen.

above with reference to formula I except that R_{19} is not hydroxy, from the corresponding compounds wherein X_1R_3 is hydroxy.

The compounds of formula IA wherein A is $CH(C_1-C_6 \text{ alkyl})$, or $CH(CH_2)_n(C_3-C_8 \text{ alkenyl})$ wherein n is 0 to 4 (having formula IB, not shown) may be prepared from the compounds of formula IX by reaction with a Grignard reagent of the formula $R_{19}MgHal$ wherein R_{19} is $C_1-C_6 \text{ alkyl}$, or $(CH_2)_n(C_3-C_8 \text{ alkenyl})$ wherein n is 0 to 4, in a conventional manner, e.g. in diethyl ether or tetrahydrofuran solvent at about -78° to $50^\circ C$, to form a ketone of the formula



15


The ketone XVI may be converted to the corresponding enamine by reaction with a compound of the formula ZH wherein Z is (a) to (d) as defined above under standard acid catalyzed dehydrogenation conditions. The enamine may be converted into the compounds of formula IA wherein A is CHR_{19} by hydrogenation with hydrogen under pressure in the presence of a noble metal catalyst or reduction with a hydride such as sodium or lithium cyanoborohydride in diethylether or tetrahydrofuran (THF).

Alternatively, the compounds of formula IB may be prepared from compounds IX by reaction with ZH wherein Z is (a) to (d) as defined above in the presence of a hydride reducing agent such as sodium or lithium cyanoborohydride.

25 The compounds of formula IA wherein A is $C(C_1-C_6 \text{ alkyl})_2$, $C(C_1-C_6 \text{ alkyl})(C_3-C_8 \text{ alkenyl})$ or $C(C_3-C_8 \text{ alkenyl})_2$ may be prepared from the compound of formula IX by reaction with concentrated hydrochloric acid under reflux to form a compound of the formula

30

-15-



5

The compound XVII may be brominated, e.g. with pyridinium bromide in THF, to form the corresponding 4-bromide of formula XVIII (not shown) which may be 4-metalated in situ, such as with t-butyl lithium in diethyl ether at -78°C, and then treated in situ with

10 an iminium compound of the formula
$$\begin{matrix} (+) & R_{19} & (-) \\ Z = & C & X \\ & R_{20} & \end{matrix}$$
 wherein R_{19} is as defined


above, R_{20} is R_{19} , Z is (a) to (d) as defined above, and X is halogen.

The compounds of formula IA wherein A is CHR_{19} wherein R_{19} is as defined above, Z is (h) or (i) as defined above and R^{14} does not have acidic hydrogens, such as hydroxyls, may be prepared from compounds of the formula I wherein Z is (h) or (i)

15 and the other substituents are as defined above with reference to formula I by treatment with a strong base such as t-butyl lithium in ether or THF and subsequent alkylation in the same solvent with a halide of the formula $R_{19}X$ wherein R_{19} and X are as defined above.

When the compounds of the invention contain a chiral center, it is understood

20 that the invention includes the racemic mixture and the individual enantiomers of such compounds. For instance, the compounds of the invention wherein Z is 1,2,3,4-tetrahydroisoquinolinyl have a chiral center when Z is substituted at position 3 by R_5 , wherein R_5 is as defined with reference to formula I except hydrogen, as follows:




wherein the chiral center is indicated by an asterisk.

-16-

Preferred compounds of the invention of formula I or IA include those derived from the dextrorotatory (+) enantiomer of the intermediate compound ZH of the formula:

5



wherein R_5 is hydroxymethyl or $(C_1-C_6 \text{ alkoxy})\text{methyl}$.

The acid addition salts are prepared in a conventional manner by treating a solution or suspension of the free base of formula I or IA with one chemical equivalent of a pharmaceutically acceptable acid. Conventional concentration or crystallization techniques are employed in isolating the salts. Illustrative of suitable acids are acetic, lactic, succinic, maleic, tartaric, citric, gluconic, ascorbic, benzoic, cinnamic, fumaric, sulfuric, phosphoric, hydrochloric, hydrobromic, hydroiodic, sulfamic, sulfonic acids such as methanesulfonic, benzenesulfonic, p-toluenesulfonic, and related acids.

The compound of the invention may be administered alone or in combination with pharmaceutically acceptable carriers, in either single or multiple doses. Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and various organic solvents. The pharmaceutical compositions formed by combining the novel compounds of formula I or IA and the pharmaceutically acceptable carriers are then readily administered in a variety of dosage forms such as tablets, powders, lozenges, syrups, injectable solutions and the like. These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like. Thus, for purposes of oral administration, tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrants such as starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes. Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules. Preferred materials for this include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration, the essential active ingredient therein may be combined with various sweetening or

flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and combinations thereof.

For parenteral administration, solutions of the novel compound of formula I in
5 sesame or peanut oil, aqueous propylene glycol, or in sterile aqueous solution may be employed. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. The sterile aqueous media employed are all readily
10 available by standard techniques known to those skilled in the art.

Additionally, it is possible to administer the compounds of the present invention topically when treating inflammatory conditions of the skin and this may be done by way of creams, jellies, gels, pastes, and ointments, in accordance with standard pharmaceutical practice.

15 The effective dosage for the compound of formula I or IA depends on the intended route of administration and other factors such as age and weight of the patient, as generally known to a physician. The dosage also depends on the illness to be treated, although the daily dosage for the illnesses to be treated according to the invention, as listed above, will generally range from about 0.1 to about 50 mg/kg of the
20 body weight of the patient to be treated. More specifically, for treatment of inflammatory diseases about 0.1 to about 100 mg/kg will be needed, for Alzheimer's disease about 0.1 to about 50 mg/kg, as well as for stress-induced illnesses, gastrointestinal diseases, anorexia nervosa, hemorrhagic stress, drug and alcohol withdrawal symptoms, and fertility problems.

25 The methods for testing the compounds of formula I or IA for their CRF antagonist activity are as described in Endocrinology, 116, 1653-1659 (1985) and Peptides, 10, 179-188 (1985) which determine the binding activity of a test compound to a CRF receptor. The binding activity for the compounds of formula I and IA generally ranges from about 0.2 nanomolar to about 10 micromolar..

30 The following Examples illustrate the invention.

Example 1A. 5-Amino-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carboxylic acid methyl ester

An ethanol (3.5 l) solution of 2-cyano-3,3-bis-methylsulfanyl-acrylic acid methyl ester (454.3 g, 2.23 mol) and 2,4,6-trichlorophenylhydrazine (472.7 g, 2.23 mol) was vigorously refluxed for 1.5 hours. The reaction mixture was allowed to stand overnight at ambient temperature. Water (850 ml) was added, and the resulting mixture was briskly stirred for 30 minutes. The granular precipitate was filtered and washed with a water/ethanol(1:3 in volume)solution (1 l). The air-dried product was further dried under vacuum (45°C) for 2 days to afford the title compound as a yellow crystalline solid, m.p. 160-162°C.

B. 5-Dimethylamino-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carboxylic acid methyl ester

To a well-stirred and ice-bath-chilled slurry of sodium hydride (232.4 g of 60% sodium hydride mineral oil dispersion, 139.4 g, 5.81 mol of sodium hydride) in anhydrous tetrahydrofuran (4 l), 711.6 g of the compound of Step A (1.94 mol) dissolved in anhydrous tetrahydrofuran was rapidly added dropwise, followed by slow dropwise addition of methyl iodide (1376 g, 9.7 mol). The reaction was then stirred at ambient temperature under nitrogen for 18 hours. The solvent was removed in vacuo. Ethyl acetate (2 l) and water (3 l) were added to dissolve the residue. The separated aqueous phase was extracted twice with 2 l portions of ethyl acetate. The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate and concentrated in vacuo to afford the title compound as an amorphous solid in quantitative yield.

¹³C NMR (CDCl₃): 163.0, 156.9, 152.7, 136.0, 135.8, 134.2, 128.8, 51.1, 42.0, 13.4.

C. (5-Dimethylamino-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-yl)-methanol

To a well-stirred/ice-bath-chilled solution of the compound of Step B (322 g, 0.816 mol) in anhydrous tetrahydrofuran (4.5 l), diisobutylaluminum hydride (2.863 l of a 1.0 M tetrahydrofuran solution, 2.86 mol) was added dropwise over 2 hours. The reaction mixture was then stirred for an additional 40 minutes at 0-5°C prior to quenching (with ice-bath cooling) by addition of methanol (400 ml). A 1:1 (in volume)

saturated aqueous Rochelle Salts/water solution (4 l), and ethyl acetate (3 l) was added, with good stirring. The organic phase was separated, extracted sequentially with equal volumes of water and brine, and finally, dried with anhydrous magnesium sulfate. Concentration in vacuo afforded a solid residue which crystallized from cyclohexane (3 l) to afford the title compound 132 g as a colorless crystalline solid, m.p. 108-110°C.

Example 2

A. 5-Amino-1-(2,6-dichloro-4-trifluoromethyl-phenyl)-3-methyl-sulfanyl-1H-pyrazole-4-carboxylic acid methyl ester

2-Cyano-3,3-bis-methylsulfanyl-acrylic acid methyl ester (49.8 g, 0.245 mol) and 2,6-dichloro-4-trifluoromethylphenylhydrazine (60.0 g, 0.245 mol) in anhydrous ethanol (390 ml) were combined, and the reaction mixture was vigorously refluxed for 1.5 hours. To the still-warm, well-stirred solution, water (480 ml) was added continuously (dropwise, rapid stream) over 10 minutes. Overnight stirring at ambient temperature afforded a heavy colorless solid precipitate of the title compound, isolated by suction filtration and in vacuo drying (80.7 g).

¹H NMR (CDCl₃): 2.44 (3H, s), 3.82 (3H, s), 5.18 (2H, s), 7.73 (2H, s).

B. 1-(2,6-Dichloro-4-trifluoromethyl-phenyl)-5-dimethylamino-3-methylsulfanyl-1H-pyrazole-4-carboxylic acid methyl ester

To a well-stirred solution of the compound of Step A (35.4 g, 88.45 mmol) and methyl iodide (55.08 ml, 125.53 g, 0.884 mol) in anhydrous tetrahydrofuran (255 ml) chilled to 5°C, sodium hydride (10.62 g of 60% sodium hydride in mineral oil dispersion; 6.37 g, 0.266 mol of sodium hydride) was added portionwise over 10 minutes. The mixture was then vigorously refluxed for 5 hours. Inspection by thin layer chromatography showed complete reaction. The mixture was concentrated in vacuo to a solid which was then dissolved in an ethyl acetate/water mixture (150 ml of each), with the pH adjusted to 9 with sodium carbonate. The organic extract was separated, dried over anhydrous sodium sulfate, and concentrated in vacuo to afford the title compound as a colorless amorphous solid, 41.16 g.

¹H NMR (CDCl₃): 2.44 (3H, s), 2.72 (6H, s), 3.86 (3H, s), 7.71 (2H, s).

C. [1-(2,6-Dichloro-4-trifluoromethyl-phenyl)-5-dimethyl-amino-3-methylsulfanyl-1H-pyrazol-4-yl]-methanol

To a well-stirred solution of the compound of Step B (6.4 g, 14.9 mmol) in anhydrous tetrahydrofuran (175 ml) maintained at -78°C, diisobutyl aluminum hydride

in toluene (49.3 ml of a 1.0 M solution, 49.3 mmol was slowly added dropwise over 10 minutes. Thin layer chromatography inspection of an aliquot after 20 minutes of stirring at -78°C showed incomplete reaction. The reaction mixture was immediately warmed to ambient temperature. Within 20 minutes at ambient temperature, reaction was found to be complete. (In addition to the desired product, a less polar byproduct identified as the corresponding C-4 methyl derivative, is formed). Methanol (162 ml) was added, cautiously at first, to quench the reaction. Warming of the mixture to 35°C for 15 minutes produced a granular precipitate. The reaction was concentrated in vacuo to a solid, which was extracted with ethyl acetate (150 ml). The solids were separated from the organic extract by filtration. The filtrate was concentrated in vacuo to an oil. Flash chromatography of the entire sample (silica gel, 40 micron mesh; elution with ethyl acetate/hexane, 1:3 in volume) afforded 1.93 g of the title compound as a colorless amorphous foam.

¹H NMR (CDCl₃): 2.50 (3H, s), 2.70 (6H, s), 4.50 (2H, s), 7.70 (2H, s).

15

Example 3

A. 5-Amino-1-(4-bromo-2,6-dimethyl-phenyl)-3-methyl-sulfanyl-1H-pyrazole-4-carboxylic acid methyl ester

In accordance with Example 2A, 4-bromo-2,6-dimethylphenylhydrazine (11.17 g, 55 mmol) was reacted with 2-cyano-3,3-bis-methylsulfanyl-acrylic acid methyl ester (13.8 g, 55 mmol) in 90 ml of ethanol. The title compound was obtained as a light-yellow amorphous solid, 13.0 g.

¹H NMR (CDCl₃): 2.06 (6H, s), 2.48 (3H, s), 3.86 (3H, s), 4.94 (2H, s), 7.32 (2H, s).

B. 1-(4-Bromo-2,6-dimethyl-phenyl)-5-dimethylamino-3-methylsulfanyl-1H-pyrazole-4-carboxylic acid methyl ester

Utilizing the compound of Step A (13.0 g, 35 mmol, sodium hydride (4.2 g of 60% sodium hydride in mineral oil dispersion, 105 mmol of sodium hydride), methyl iodide (10.9 ml, 175 mmol) and tetrahydrofuran (90 ml) as solvent, the method of Example 1B afforded the title compound (14.15 g) as a yellow amorphous solid.

¹³C NMR (CDCl₃): 163.1, 155.5, 151.2, 138.5, 136.8, 131.3, 122.8, 100.8, 51.0, 42.0, 17.6, 13.4.

-21-

C. [1-(4-Bromo-2,6-dimethyl-phenyl)-5-dimethyl-amino-3-methylsulfany-1H-pyrazol-4-yl]-methanol

Utilizing the compound of Step B (12.0 g, 30 mmol), diisobutylaluminum hydride (100 ml of a 1.0 M toluene solution, 100 mol), and anhydrous tetrahydrofuran (170 ml), the title compound was prepared by the method of Example 2C (3.6 g, isolated as a colorless oil.

¹³C NMR (CDCl₃): 151.8, 148.1, 138.7, 137.2, 131.1, 122.3, 106.7, 61.7, 42.6, 17.8, 15.7.

Example 4

10 A. 5-Amino-3-methyl-1-(2,4,6-trichloro-phenyl)-1H-pyrazole-4-carboxylic-acid methyl ester

To a solution of 2-cyano-3-methyl-3-ethoxy-acrylic acid methyl ester (3.5 g, 0.021 mol) in glacial acetic acid (20 ml), 2,4,6-trichlorophenylhydrazine (4.38 g, 0.021 mol) was added with stirring, followed by triethylamine (2.0 ml, 1.46 g, 0.014 mol). The reaction was refluxed for 13 hours. Solvent removal in vacuo afforded a dark oil, which was dissolved in methylene chloride/water (100 ml of each). The separated organic phase was extracted with an equal volume of water, dried over anhydrous sodium sulfate, and concentrated in vacuo to an orange oil (5.8 g). Flash chromatography of the entire sample (silica gel, 40 micron mesh; elution with ethyl acetate/hexane=1:3 in volume) afforded the title compound (3.20 g) as a light-orange amorphous solid. Thin layer chromatography (TLC) R_f (silica gel plates, u.v. detection, ethyl acetate/hexane=1:3 in volume): 0.43.

B. 5-Dimethylamino-3-methyl-(2,4,6-trichloro-phenyl)-1H-pyrazole-4-carboxylic acid methyl ester

25 To a well-stirred and ice-bath-chilled solution of the compound of Step A (3.2 g, 9.6 mmol) and methyl iodide (3.0 ml, 6.84 g, 48 mmol) in anhydrous tetrahydrofuran (20 ml), sodium hydride (1.15 g of 60% sodium hydride mineral oil dispersion, 690 mg, 29 mmol of sodium hydride) was added portionwise. The reaction mixture was stirred at 5°C for 15 minutes; then an ambient temperature for 20 hours. Concentration in vacuo afforded a light-yellow solid, which was dissolved in ethyl acetate/water (100 ml of each) with the pH adjusted to 12 with sodium carbonate. The separated aqueous phase was twice extracted with 50 ml portions of ethyl acetate. The three combined organic extracts were dried over anhydrous sodium sulfate and concentrated in vacuo

-22-

to afford the title compound (3.5 g) as an orange amorphous solid. TLC R_f (silica gel plates, u.v. detection, ethyl acetate/hexane=1:3 in volume): 0.73.

C. [5-Dimethylamino-3-methyl-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-yl]-methanol

5 To a well-stirred solution of the compound of Step B (350 mg, 0.96 mmol) in anhydrous tetrahydrofuran (3 ml) chilled to -78°C, diisobutylaluminum hydride (2.90 ml of 1.0 M diisobutylaluminum hydride in tetrahydrofuran; 2.9 mmol of diisobutylaluminum hydride) was added dropwise. After stirring for one hour at -78°C and an additional hour at 5°C, the reaction was stirred at ambient temperature for 2 hours. The reaction
10 was then quenched by dropwise (at 5°C) addition of methanol (7 ml). The mixture was stirred for 15 minutes at ambient temperature, and then for 10 minutes at 35-40°C. Concentration in vacuo afforded a yellow solid which was extracted with ethyl acetate (7 ml). The remaining insoluble solids were removed by filtration. The filtrate was extracted with an equal volume of water, dried (anhydrous sodium sulfate), and
15 concentrated in vacuo to afford the title compound as a light-orange oil (0.32 g). The product was used in the next step without further purification.

D. Enantiomeric {2-[5-Dimethylamino-3-methyl-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-yl-methyl]-1,2,3,4-tetrahydro-isoquinolin-3-yl}-methanol

To an ice-bath-chilled, well-stirred solution of the compound of Step C (160 mg, 0.48 mmol and triethylamine (0.08 ml, 0.60 mmol) in anhydrous methylene chloride (3 ml), methanesulfonyl chloride (0.04 ml, 59.2 mg, 0.52 mmol) was added all at once. After 15 minutes of stirring at 5°C to complete in situ formation of the mesylate of the compound of Step C, the dextrorotatory enantiomer of 3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline (310 mg, 1.9 mmol), anhydrous N,N-dimethylformamide (0.51 ml)
25 and acetonitrile (1.2 ml) were added. After stirring 1/2 hour at ambient temperature, the reaction mixture was heated at 55°C for 19 hours. Concentration in vacuo afforded an orange residue which was dissolved in ethyl acetate/water (100 ml of each) with the pH adjusted to 10 with sodium carbonate. The separated aqueous phase was extracted twice with 50 ml portions of ethyl acetate. The combined organic extracts were dried
30 over anhydrous sodium sulfate and concentrated in vacuo to an orange semi-solid (0.7 g). Flash chromatography of the entire sample (silica gel, 40 micron mesh; eluting with ethyl acetate/hexane=1.3 volume) afforded the title compound (170 mg) as a light-orange oil.

^{13}C NMR (CDCl_3): 151.6, 151.0, 136.2, 135.3, 135.0, 133.6, 133.3, 129.0, 128.6, 127.0, 126.5, 126.1, 107.5, 62.0, 58.0, 47.6, 45.6, 42.6, 26.2, 13.1.

Example 5

A. 2-Cyano-3,3-diethoxy-acrylic acid methyl ester

5 A reaction mixture consisting of methylcyanoacetate (5.0 ml, 57 mmol) and tetraethylorthocarbonate (17.99 ml, 86 mmol) in acetic anhydride (8.11 ml, 86 mmol) was heated at 130°C for 5 hours, and then heated at 110°C for 18 hours. The cooled reaction residue was extracted twice with 125 ml portions of hexane. A hexane-insoluble orange oil containing approximately 40% by weight of the desired compound
10 (as established by NMR inspection) remained. This crude product was used in the next step without further purification. TLC R_f (silica gel plates, u.v. detection, ethyl acetate/hexane=15:85 in volume): 0.13.

B. 5-Amino-3-ethoxy-1-(2,4,6-trichloro-phenyl)-1H-pyrazole-4-carboxylic acid methyl ester

15 The crude product obtained in Step A (4.76 g, containing approximately 1.9 g, 9.6 mmol of 2-cyano-3,3-diethoxy-acrylic acid methyl ester) was combined with 2,4,6-trichlorophenyhydrazine (2.02 g, 9.6 mmol) in ethanol (15 ml). The resulting mixture was refluxed for 18 hours. The solvent was removed in vacuo, and the residue was extracted with methylene chloride/water (100 ml of each) with the pH adjusted to 10
20 with sodium carbonate. The separated aqueous extract was washed with two 50 ml portions of methylene chloride. The three combined organic extracts were dried over anhydrous sodium sulfate and concentrated in vacuo to an oil (5.98 g). The purity of this crude title compound was significantly improved by flash chromatography (silica gel, 40 micron mesh; elution with ethyl acetate/hexane=15:85 in volume), yielding 910
25 mg of the title compound as an orange oil. TLC R_f (silica gel plates, u.v. detection; ethyl acetate hexane=15.85 in volume): 0.26. The product was used in the next step without further purification.

C. 5-Dimethylamino-3-ethoxy-1-(2,4,6-trichloro-phenyl)-1H-pyrazole-4-carboxylic acid methyl ester

30 To an ice-bath-chilled solution of the compound of Step B (910 mg, 2.5 mmol) and methyl iodide (778 μl , 12.5 mmol) in anhydrous tetrahydrofuran (10 ml), sodium hydride (300 mg of 60% sodium hydride mineral oil dispersion; 180 mg, 7.5 mmol of sodium hydride) was added portionwise over 5 minutes. The reaction mixture was

-24-

stirred at ambient temperature for 18 hours. The solvent was removed in vacuo, and the residue was extracted into methylene chloride/water (60 ml of each). The separated aqueous phase was extracted twice with 30 ml portions of methylene chloride. The organic extracts were combined, dried over anhydrous sodium sulfate, and concentrated in vacuo to an amber oil (980 mg). Flash chromatography of the entire sample (silica gel, 40 micron mesh; elution with ethyl acetate/hexane=5:95 in volume) afforded the title compound as a colorless oil (353 mg.)

TLC R_f (silica gel plates, u.v. detection, ethyl acetate/hexane=5:95 in volume): 0.26.

10 D. [5-Dimethylamino-3-ethoxy-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-yl]-methanol

Utilizing the procedure of Example 2C, the compound of Step 5C (340 mg, 0.87 mmol) was converted into the corresponding alcohol (230 mg of colorless oil). The product after workup (without chromatography) was used in the next step without further purification.

TLC R_f (silica gel plates, u.v. detection, ethyl acetate/hexane=15:85 in volume): 0.20.

E. Enantiomeric {2-[5-Dimethylamino-3-ethoxy-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-ylmethyl]-1,2,3,4-tetrahydroisoquinoline-3-yl}-methanol

20 To a well-stirred/ice-bath-chilled methylene chloride (1 ml) solution of the compound of Step 5D (estimated 69 mg, 0.19 mmol) and triethylamine (32 μ l, 0.23 mmol), methanesulfonyl chloride (16 μ l, 0.21 mmol) was added. After 15 minutes of stirring, the dextrorotatory isomer of 3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline (124 mg, 0.72 mmol) and anhydrous N,N-dimethylformamide (0.1 ml) were added; and the resulting mixture was heated at 50°C for 4 hours. After ambient temperature stirring for an additional 48 hours, the solvent was removed in vacuo, and the residue was extracted into methylene chloride/water (60 ml of each) with the pH adjusted to 10 (sodium carbonate). The separated aqueous phase was extracted twice with 30 ml portions of methylene chloride. The combined organic extracts were dried (anhydrous sodium sulfate) and concentrated in vacuo to an oil (410 mg). Flash chromatography of the entire sample (silica gel, 40 micron mesh; elution with ethyl acetate/hexane=1:4 in volume) afforded the title compound (7 mg) as a colorless foam.

-25-

¹H NMR (CDCl₃); (3H, t, J=8 Hz), 2.5-2.8 (7H; 6H, s overlapping with 1H, m), 2.95 (1H, dd), 3.2-4.1 (7H, broad, overlapping multiplets) 4.25 (2H, q, J=8 Hz), 6.96-7.38 (4H, broad m), 7.45 (2H, s).

Example 6

5 Enantiomeric {2-[1-(4-Bromo-2,6-dimethyl-phenyl)-5-dimethylamino-3-methyl-sulfanyl-1H-pyrazol-4-ylmethyl]-1,2,3,4-tetrahydro-isoquinoline-3-yl}-methanol

Utilizing the dextrorotatory isomer of 3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline (528 mg, 3.24 mmol) dissolved in acetonitrile/anhydrous N,N-dimethylformamide (15 ml and 0.5 ml, respectively) and the in situ-generated mesylate
10 of Example 3C (300 mg, 0.81 mmol), triethylamine (169 μ l, 1.20 mmol), and methanesulfonyl chloride (81.5 μ l, 1.05 mmol) in anhydrous methylene chloride (6 ml)] the title compound (21 mg, 5% yield) was prepared as a colorless amorphous solid by the Example 4D coupling method/workup and flash chromatography (silica gel, 40 micron mesh; elution with ethyl acetate/hexane=1:9 in volume).

15 TLC R_f (silica gel plates, u.v. detection, ethyl acetate/hexane=1:4 in volume): 0.30. HRMS m/z 514.1402 (M, C₂₅H₃₀BrN₄OS).

Example 7

Racemic {2-[5-Dimethylamino-3-methylsulfanyl-1-(2,4,6-trichloro-phenyl)-1H-pyrazol-4-ylmethyl]-1,2,3,4-tetrahydro-isoquinolin-3-yl}-methanol

20 To a stirred solution of the compound of Example 1C (700 mg, 1.9 mmol) and triethylamine (0.304 ml, 2.2 mmol) in anhydrous methylene chloride chilled to 5°C, methanesulfonyl chloride (0.164 ml, 2.1 mmol) was added to form the corresponding mesylate in situ. The reaction mixture was stirred at 5°C for 25 minutes. A solution of (+)-3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline (1.24 g, 7.6 mmol) in
25 acetonitrile/anhydrous N,N-dimethylformamide (5 ml and 1.5 ml, respectively) was added, and the reaction mixture was heated with a 55-60°C oil bath for 18 hours. The solvent was removed in vacuo, and the residue was dissolved in a ethyl acetate/water mixture (100 ml of each) with the pH adjusted to 9.5 (sodium carbonate). The organic extract was separated, dried over anhydrous sodium sulfate, and concentrated in vacuo
30 to an amber glass. Flash chromatography of the entire sample (silica gel, mesh; elution with ethyl acetate, hexane=1:10 in volume) afforded the title compound (800 mg) as a colorless amorphous solid.

^{13}C NMR: (CDCl_3): 151.8, 149.6, 136.2, 135.5, 134.7, 133.6, 133.4, 129.0, 128.7, 127.1, 126.4, 126.0, 108.7, 62.2, 57.7, 48.3, 45.3, 42.8, 25.9, 14.7.

Example 8

5 Enantiomeric {2-[5-Dimethylamino-3-methylsulfanyl-1-(2,4,6-trichloro-phenyl)-1H-pyrazol-4-ylmethyl]-1,2,3,4-tetrahydro-isoquinolin-3-yl}-methanol

To a stirred solution of the compound of Example 1C (258 mg, 0.704 mmol) and triethylamine (0.112 ml, 0.80 mmol) in anhydrous methylene chloride chilled to +5°C, methanesulfonyl chloride (0.061 ml, 0.79 mmol) was added to form the corresponding mesylate in situ. The reaction was stirred at 5°C for 20 minutes. A solution of the
10 dextrorotatory enantiomer of 3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline (230 mg, 1.4 mmol) in acetonitrile/anhydrous N,N-dimethylformamide (2.5 ml and 1 ml, respectively) was added, and the resulting mixture was heated with a 60°C oil bath for 18 hours. The solvent was removed in vacuo and the resulting solid residue was dissolved in methylene chloride/water (25 ml of each) with the pH adjusted to 9.5
15 (sodium carbonate). The organic phase was separated, washed with an equal volume of water, dried (anhydrous sodium sulfate), and concentrated in vacuo to a solid. The entire sample was pulped in isopropyl alcohol (3 ml). After stirring for 1 hour at ambient temperature, a solid byproduct was filtered. The filtrate was concentrated in vacuo to an oil (0.41 g). Flash chromatography of the entire sample (silica gel, 40
20 micron mesh; elution with ethyl acetate/hexane=1:5 in volume) afforded the title compound (60 mg) as a colorless amorphous solid.

^{13}C NMR (CDCl_3): identical to that of the racemic compound prepared in Example 7.

25

Example 9

Enantiomeric {2-[Dimethylamino-3-methylsulfanyl-1-(2,4,6-trichloro-phenyl)-1H-pyrazol-4-ylmethyl]-1,2,3,4-tetrahydro-isoquinolin-3-yl}-methanol

Following the procedure of Example 4D, and utilizing the levorotatory enantiomer of 3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline as the nucleophilic
30 substrate, the title compound was prepared as a colorless amorphous solid.

^{13}C NMR spectrum: identical in all respects to the one for the title (racemic) compound of Example 7.

-27-

Example 10

Enantiomeric {2-[1-(2,6-Dichloro-4-trifluoromethyl-phenyl)-5-dimethylamino-3-methyl-sulfanyl-1H-pyrazol-4-ylmethyl]-1,2,3,4-tetrahydro-isoquinolin-3-yl}-methanol 23

Utilizing the dextrorotatory enantiomer of 3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline (376 mg, 2.3 mmol) dissolved in acetonitrile/anhydrous N,N-dimethylformamide (1.5 ml and 0.5 ml, respectively) and the in situ-generated mesylate of the compound of Example 2C, the title compound (56 mg) was obtained as a colorless oil by the method of Example 4D and flash chromatography (silica gel, 40 micron mesh; elution with methanol/methylene chloride=1:4 in volume). TLC R_f (silica gel plates, u.v. detection, methanol/methylene chloride=1:4 in volume): 0.4. HRMS m/z 544.1078 (M, $C_{24}H_{24}Cl_2F_3N_4OS$). 5 10

Example 11

A. Racemic (2,3-Dihydro-1H-indol-2-yl)-methanol

Racemic 2,3-dihydro-1H-indole-2-carboxylic acid (5.0 g, 30.6 mmol) was suspended in methanol (50 ml). Sodium methoxide (1.66 g, 30.6 mmol) was added, and the resulting slurry was stirred several minutes before the solvent was removed in vacuo. The entire sample was suspended in anhydrous tetrahydrofuran (60 ml). Lithium aluminum hydride (1.0 M solution in tetrahydrofuran; 30.6 ml, 30.6 mmol) was added dropwise over 15 minutes. The reaction mixture was refluxed for 3 hours. The ice-bath-chilled mixture was then cautiously quenched by dropwise addition of 15 percent aqueous sodium hydroxide (4 ml). The reaction was filtered, and the filtrate was concentrated in vacuo to afford (+)-2-hydroxymethyl-indoline (3.69 g) as a viscous brown oil, used in the next step without further purification. TLC R_f (silica gel plates; u.v. detection, elution with ethyl acetate/hexane=1:4 in volume): 0.15. 15 20 25

B. Racemic {1-[5-Dimethylamino-3-methylsulfanyl-1-(2,4,6-trichloro-phenyl)-1H-pyrazol-4-ylmethyl]-2,3-dihydro-1H-indol-2-yl}-methanol

By the procedure of Example 4D, the racemic mixture of Step A (895 mg, 6 mmol) was reacted with the in situ prepared mesylate derived from 500 mg (1.5 mmol) of the compound of Example 1C. Flash chromatography (silica gel, 40 micron mesh, eluting with ethyl acetate/hexane=1:4 in volume) of the crude product after workup as described in Example 4D afforded the title compound as a colorless oil (124 mg). 30

-28-

^{13}C NMR (CDCl_3): 153.0, 150.7, 148.6, 136.2, 135.7, 135.0, 129.6, 128.7, 127.2, 124.5, 119.2, 109.7, 108.9, 67.8, 63.1, 45.1, 42.8, 31.7, 14.4.

Example 12

A. 2-Benzyl-4H-isoquinoline-1,3-dione

5 A mixture consisting of homophthalic acid (25 g, 0.139 mol) and benzylamine (15.2 ml, 14.91 g, 0.139 mol) was heated at 165-180°C for two hours, producing a vigorous release of water vapor. Cooling afforded a hard green solid which was pulverized, triturated with diethyl ether, and isolated by filtration to afford the title compound as a light-green granular solid (29.4 g) used in the next step without further
10 purification.

TLC R_f (silica gel plates; u.v. detection, eluting with ethyl acetate/hexane=15:85 in volume): 43; ^{13}C NMR (CDCl_3): 169.9, 164.8, 137.1, 134.1, 133.7, 129.3, 129.0, 128.4, 127.7, 127.5, 127.1, 125.4, 43.3, 36.5.

B. Racemic 2-Benzyl-3-hydroxy-3,4-dihydro-2H-isoquinoline-1-one

15 To a well-stirred ice-bath-chilled solution of 2-benzyl-4H-isoquinoline-1,3-dione (5.0 g, 20 mmol) in methanol (40 ml), sodium borohydride (3.0 g, 80 mmol) was added portionwise over 20 minutes. The reaction mixture was stirred at ambient temperature for 48 hours. TLC inspection of a reaction aliquot confirmed substantial formation of product, with some starting material remaining. TLC R_f of the title compound (silica gel
20 plates; u.v. detection; elution with ethyl acetate/hexane=3.7 in volume): 0.24. The ice-bath-chilled reaction mixture was cautiously quenched with water (3 ml). Anhydrous sodium sulfate was added to dry the mixture, which was then filtered. The filtrate was concentrated in vacuo to a dark green oil (3.5 g). Flash chromatography (silica gel, 40 micron mesh; elution with ethyl acetate hexane=3.7 volume) afforded the title
25 compound as a colorless amorphous solid (1.35 g). The labile material was used immediately in the next step.

C. Racemic (2-Benzyl-1-oxo-1,2,3,4-tetrahydro-isoquinolin-3-yl)-acetic acid methyl ester

Sodium hydride (307 mg of 60% sodium hydride mineral oil dispersion; 184 mg, 7.7 mmol of sodium hydride) was added portionwise over several minutes to a well-
30 stirred, ice-bath-chilled solution of the racemic mixture of Step B (1.35 g, 5.34 mmol) in anhydrous tetrahydrofuran (20 ml). Methyl diethylphosphonoacetate (1.76 ml, 2.015 g, 9.6 mmol) was added portionwise over several minutes, and the resulting mixture

was then stirred for 24 hours at ambient temperature. The solvent was removed in vacuo, and the residue was dissolved in ethyl acetate/water (50 ml of each). The separated aqueous extract was extracted twice with 10 ml portions of ethyl acetate. The combined organic extracts were dried over anhydrous sodium sulfate and concentrated in vacuo to a brown oil (2.4 g). Flash chromatography of the entire sample (silica gel, 40 micron mesh; elution with ethyl acetate/hexane=15:85 in volume) afforded the title compound (650 mg), as a colorless viscous oil.

^{13}C NMR (CDCl_3): 171.3, 163.7, 137.8, 135.6, 132.2, 128.9, 128.7, 128.3, 128.1 (2), 127.6, 127.3, 51.8, 51.7, 48.7, 36.2, 32.5.

10 D. Racemic 2-(2-Benzyl-1,2,3,4-tetrahydro-isoquinolin-3-yl)-ethanol

To a well-stirred ice-bath-chilled solution of the racemic mixture of Step C (650 mg, 2.0 mmol) in anhydrous tetrahydrofuran (10 ml), a solution of lithium aluminum hydride in tetrahydrofuran (6.11 ml of a 1.0M solution, 6.11 mmol of lithium aluminum hydride) was added dropwise over 5 minutes. The reaction mixture was then stirred for 24 hours at ambient temperature before being ice-bath-chilled and cautiously quenched with 15% aqueous sodium hydroxide (2 ml). Anhydrous sodium sulfate was added to dry the mixture, which was then filtered. The filtrate was concentrated in vacuo to afford the title compound as a colorless oil in quantitative yield.

20 TLC R_f (silica gel plates; u.v. detection, elution with ethyl acetate/hexane=1:4 in volume): 0.21.

E. Racemic 2-(1,2,3,4-Tetrahydro-isoquinolin-3-yl)-ethanol

(+)-2-(2-Benzyl-1,2,3,4-tetrahydro-isoquinolin-3-yl)-ethanol (610 mg, 2.3 mmol) was hydrogenated at 40 p.s.i.g. on a Parr Apparatus (305 mg of 10% palladium-on-carbon catalyst; methanol/concentrated hydrochloric acid solvent (15 ml and 0.25 ml, respectively) for 5 hours. The catalyst was filtered, and the filtrate was concentrated in vacuo to an oil, which was dissolved in dilute aqueous (pH 9) sodium carbonate/methylene chloride (50 ml of each). The aqueous phase was separated and extracted with two 10 ml portions of methylene chloride. The combined organic extracts were dried over anhydrous sodium sulfate and concentrated in vacuo to afford the title compound as a viscous colorless oil (quantitative yield).

30 ^{13}C NMR (CDCl_3): 135.4, 134.2, 129.3, 126.3, 126.1, 125.9, 63.2, 55.5, 47.9, 37.2, 35.5.

F. Racemic 2-{2-[5-Dimethylamino-methylsulfanyl-1-(2,4,6-trichloro-phenyl)-1H-pyrazol-4-ylmethyl]-1,2,3,4-tetrahydro-isoquinolin-3-yl}-ethanol

Racemic 2-(1,2,3,4-tetrahydro-isoquinolin-3-yl)-ethanol (400 mg, 2.4 mmol) was reacted with the in situ-prepared mesylate of the compound of Example 1C by the method of Example 4D affording the title compound (80 mg) as a colorless viscous oil.

¹³C NMR (CDCl₃): 151.9, 149.8, 136.2, 135.5, 134.8, 133.1 (2), 129.3, 128.7, 126.9, 126.2, 126.0, 108.0, 62.3, 55.3, 48.0, 46.1, 42.3, 32.5, 29.1, 14.8.

Example 13

[4-(3-Butoxymethyl-3,4-dihydro-1H-isoquinolin-2-ylmethyl)-5-methyl-sulfanyl-2-(2,4,6-trichloro-phenyl)-2H-pyrazol-3-yl]-dimethyl-amine

To an anhydrous tetrahydrofuran (2 ml) solution of the racemic mixture of Example 7 (0.21 g, 0.41 mmol), sodium hydride (82 mg of 60% sodium hydride mineral oil dispersion; 49 mg, 2.0 mmol of sodium hydride) was added, and the resulting mixture was stirred 10 minutes before adding n-butyliodide (0.19 ml, 307 mg, 1.7 mmol). The reaction mixture was stirred for 24 hours. Thin layer chromatography inspection of a reaction aliquot showed incomplete reaction. More sodium hydride (82 mg of 60% sodium hydride mineral oil dispersion; 49 mg, 2.0 mmol of sodium hydride), anhydrous tetrahydrofuran (0.5 ml), and n-butyliodide (0.19 ml, 307 mg, 1.7 mmol) was added; and the resulting mixture was stirred 24 hours at ambient temperature to essentially complete reaction. The solvent was removed in vacuo and the residue was dissolved in ethyl acetate/water (50 ml of each). The separated aqueous extract was extracted with three 10 ml portions of ethyl acetate. The combined organic extracts were dried (anhydrous sodium sulfate) and concentrated in vacuo to a viscous orange oil (0.3 g). Chromatography involving sequential flash and then gravity methods of elution (silica gel, 40 micron mesh; elution with ethyl acetate/hexane=1:0 in volume) afforded the title compound (150 mg), as a viscous yellow oil.

¹³C NMR (CDCl₃): 152.0, 149.9, 136.1, 135.3, 134.9, 134.7, 134.0, 129.1, 128.6, 126.4, 126.0, 125.5, 109.4, 71.1, 69.8, 56.2, 50.4, 47.9, 42.4, 31.9, 30.8, 19.4, 15.2, 13.9.

Example 14

Racemic [4-(3-Methoxymethyl-3,4-dihydro-1H-isoquinolin-2-ylmethyl)-5-methylsulfanyl-2-(2,4,6-trichloro-phenyl)-2H-pyrazol-3-yl]-dimethyl-amine

To a solution of the racemic mixture of Example 7 (200 mg, 0.39 mmol) in anhydrous tetrahydrofuran (2.0 ml), sodium hydride (78 mg of 60% sodium hydride

-31-

mineral oil dispersion; 46 mg, 2.0 mmol of sodium hydride) was added; and the resulting mixture was stirred for 15 minutes at ambient temperature. Methyl iodide (0.10 ml, 1.6 mmol) was added, and the mixture was stirred for 18 hours at ambient temperature. The solvent was removed in vacuo, and the residue was dissolved in ethyl acetate/water (20 ml of each). The aqueous phase was separated and extracted with three equal volumes of ethyl acetate. The combined organic extracts were dried (anhydrous sodium sulfate) and concentrated in vacuo to a yellow oil. Flash chromatography of the entire sample (silica gel, 40 micron mesh; elution with ethyl acetate/hexane=1:10 in volume) afforded the title compound (118 mg) as a light-yellow oil.

^{13}C NMR (CDCl_3): 152.0, 149.8, 136.1, 135.3, 134.8, 134.6, 133.9, 129.1, 128.6, 126.5, 126.1, 125.6, 109.2, 71.8, 58.9, 56.0, 50.6, 47.6, 42.4, 30.6, 15.2.

Example 15

Enantiomeric [4-(3-Methoxymethyl-3,4-dihydro-1H-isoquinolin-2-ylmethyl)-5-methylsulfanyl-2-(2,4,6-trichloro-phenyl)-2H-pyrazol-3-yl]-dimethyl-amine

To a well-stirred solution of the compound of Example 8 (200 mg, 0.39 mmol) in anhydrous tetrahydrofuran (3 ml), sodium hydride (78 mg of 60% sodium hydride mineral oil dispersion, 46.8 mg, 2.0 mmol of sodium hydride) was added. The mixture was stirred for 5 minutes at ambient temperature before methyl iodide (0.097 ml, 1.6 mmol) was added. After stirring for 16 hours at ambient temperature, the solvent was removed in vacuo, and the residue was extracted in to an ethyl acetate/water (60 ml of each) mixture. The separated aqueous phase was then extracted with three equal volume portions of fresh ethyl acetate. The combined ethyl acetate extracts were dried (anhydrous sodium sulfate) and concentrated in vacuo to an orange oil (510 mg). Flash chromatography of the entire sample (silica gel, 40 micron mesh; elution with ethyl acetate/hexane=1:10 in volume) afforded the single enantiomeric title product as a light-yellow oil (50 mg, 24% yield). The TLC R_f data and ^1H NMR ^{13}C NMR spectra were identical in all respects to those obtained with the corresponding racemic product obtained by Example 14.

30

-32-

Example 16Enantiomeric [4-(3-Isopropoxymethyl-3,4-dihydro-1H-isoquinolin-2-ylmethyl)-5-methylsulfanyl-2-(2,4,6-trichloro-phenyl)-2H-pyrazol-3-yl]-dimethyl-amine

To a well-stirred solution of the compound of Example 8 (310 mg, 0.61 mmol) in anhydrous tetrahydrofuran (3 ml), sodium hydride (140 mg of 60% sodium hydride mineral oil dispersion, 84 mg, 3.5 mmol of sodium hydride) was added. The reaction mixture was stirred at ambient temperature for 5 minutes before isopropyl iodide (0.42 ml, 4.2 mmol) was added. The reaction was then stirred at ambient temperature for 23 hours. Additional anhydrous tetrahydrofuran (1 ml) and sodium hydride (120 mg of 60% sodium hydride mineral oil dispersion, 72 mg, 3.0 mmol of sodium hydride) were added, followed 5 minutes later by a second portion of isopropyl iodide (0.30 ml, 3.0 mmol). Ambient temperature stirring was continued for an additional 5 hours. The solvent was removed in vacuo, and the residue was extracted with ethyl acetate/water (60 ml of each). The separated aqueous phase was extracted twice with 30 ml portions of fresh ethyl acetate. The combined organic extracts were dried over anhydrous sodium sulfate and concentrated in vacuo to afford an orange oil (600 mg). Chromatography (silica gel, 40 micron mesh; elution with ethyl acetate/hexane=1:10 in volume) afforded the title compound (2.0 mg) as a light-yellow oil. The TLC R_f and NMR spectral properties of the title compound are identical in all respects to those of the racemic counterpart prepared by Example 17.

Example 17Racemic [4-(3-Isopropoxymethyl-3,4-dihydro-1H-isoquinolin-2-ylmethyl)-5-methylsulfanyl-2-(2,4,6-trichloro-phenyl)-2H-pyrazol-3-yl]-dimethyl-amine

Utilizing the procedure of Example 15, the compound of Example 7 (215 mg, 0.42 mmol) in anhydrous tetrahydrofuran (2 ml) was reacted first with sodium hydride (100 mg of 60% sodium hydride mineral oil dispersion; 60 mg, 2.5 mmol of sodium hydride), and then with isopropyl iodide (0.29 ml, 497 mg, 2.9 mmol), affording the title compound (20 mg) as a yellow oil.

¹³C NMR (CDCl₃): 152.1, 149.7, 136.1, 135.3, 134.7 (2), 134.0, 129.1, 128.6, 126.4, 126.0, 125.5, 109.4, 71.9, 67.0, 56.6, 50.3, 48.0, 42.4, 30.9, 22.3, 22.1, 15.2.

-33-

Example 18

Racemic Dimethyl-{4-[3-(3-methyl-butoxymethyl)-3,4-dihydro-1H-isoquinolin-2-ylmethyl]-5-methylsulfanyl-2-(2,4,6-trichloro-phenyl)-2-pyrazol-3-yl}-amine

Utilizing the procedure of Example 16, the compound of Example 7 (210 mg, 0.41 mmol) in anhydrous tetrahydrofuran (2 ml) was reacted first with sodium hydride (100 mg of 60% sodium hydride mineral oil dispersion; 60 mg, 2.5 mmol of sodium hydride), and then with isopentyl iodide (570 mg, 2.9 mmol), affording the title compound (44 mg) as a yellow oil.

^{13}C NMR (CDCl_3): 152.0, 149.9, 136.1, 135.3, 134.7 (2), 134.0, 129.1, 128.6, 126.4, 126.0, 125.5, 109.3, 69.8, 56.2, 50.3, 47.9, 42.4, 38.6, 30.9, 25.1, 22.7, 22.6, 15.2.

Example 19

Racemic {4-[3-(2-Methoxy-ethoxymethyl)-3,4-dichloro-1H-isoquinolin-2-ylmethyl]-5-methylsulfanyl-2-(2,4,6-trichloro-phenyl)-2H-pyrazol-3-yl}-dimethyl-amine

To a solution of the compound of Example 7 (64 mg, 0.12 mmol) in anhydrous tetrahydrofuran (0.5 ml), sodium hydride (17.5 mg of 60% sodium hydride mineral dispersion; 10.5 mg, 0.44 mmol of sodium hydride) was added; and the resulting mixture was stirred for 15 minutes. 1-iodo-2-methoxy-ethane (0.1 ml, 0.5 mmol) was added. After stirring for 48 hours followed by 6 hours at reflux, thin layer chromatography inspection of an aliquot showed incomplete reaction. Additional sodium hydride (33 mg of 60% mineral oil dispersion, 20 mg, 1.0 mmol of sodium hydride), 1-iodo-2-methoxyethane (100 μl , 0.5 mmol) and anhydrous tetrahydrofuran (0.8 ml) were added; and the mixture was refluxed for 18 hours to complete reaction. The solvent was removed in vacuo, and the residue was dissolved in ethyl acetate/water (20 ml of each). The separated aqueous phase was extracted with three equal volumes of ethyl acetate. The combined organic extracts were dried over anhydrous sodium sulfate and concentrated in vacuo to afford an orange gum. Flash chromatography (silica gel, 40 micron mesh; elution with ethyl acetate/hexane=1:4 in volume) afforded the title compound (23 mg) as a light-yellow oil.

^{13}C NMR (CDCl_3): 152.1, 149.7, 136.3, 135.4, 134.7 (2), 134.0, 129.1, 128.6, 126.5, 126.0, 125.5, 109.4, 72.0, 70.5, 70.3, 59.1, 56.0, 50.2, 47.9, 42.4, 30.7, 15.2.

Example 20

Enantiomeric 2-{2-[5-Dimethylamino-3-methylsulfanyl-1-(2,4,6-trichloro-phenyl)-1H-pyrazol-4-ylmethyl]-1,2,3,4-tetrahydro-isoquinolin-3-ylmethoxy}-ethanol and the corresponding tert-butyl-dimethylsilyl ether

5 To a solution of the compound of Example 8 (100 mg, 0.195 mmol) in anhydrous tetrahydrofuran (0.2 ml), sodium hydride (18.4 mg of 60% sodium hydride mineral oil dispersion, 11.04 mg, 0.46 mmol of sodium hydride) was added; and the resulting mixture was stirred for 5 minutes at ambient temperature before adding 1-iodo-2-(tert-butyl-dimethylsilyloxy)ethane (222 mg, 0.39 mmol). The reaction was then heated
10 at 85°C for 2.5 hours. Thin layer chromatography of a reaction aliquot indicated alkylation to be complete. The solvent was removed in vacuo and the residue was dissolved in an ethylacetate/water mixture (50 ml of each). The separated organic extract was then dried over anhydrous sodium sulfate and concentrated in vacuo to a yellow oil (285 mg). Flash chromatography purification of the entire sample (silica gel,
15 40 micron mesh; eluting with ethylacetate/hexane=2.5:97.5 in volume) afforded the purified silylated title compound (14 mg) as a colorless oil.

¹³C NMR (CDCl₃): ppm 152.0, 149.9, 136.1, 135.3, 134.8, 134.6, 133.9, 129.1, 128.6, 126.4, 126.0, 125.5, 109.3, 72.7, 70.3, 62.7, 56.2, 50.5, 47.7, 42.4, 30.6, 25.9, 22.6, 18.4, 15.2. The entire sample of silylated title compound (14 mg, 0.021 mmol)
20 was dissolved in tetrahydrofuran. Tetrabutylammonium fluoride (42 µl of a 1.00 M solution in tetrahydrofuran, 0.042 mmol) was added, and the resulting mixture was stirred for 1 hour at ambient temperature. Thin layer chromatography revealed the presence of a small amount of the silylated compound. An additional 4 µl of 1.0 M tetrabutylammonium fluoride in tetrahydrofuran effected complete desilylation within 30
25 minutes. The solvent was removed in vacuo, and the residue was dissolved in an ethylacetate/water (20 ml of each) mixture. The layers were separated, and the aqueous portion was extracted twice with 10 ml portions of fresh ethyl acetate. The combined organic extracts were dried over anhydrous sodium sulfate and concentrated to an oil (20 mg). Flash chromatography of the entire sample (silica gel, 40 micron
30 mesh; elution with ethylacetate/hexane=1:3 in volume) afforded the first title compound (11.5 mg) as a colorless oil.

TLC R_f (silica gel plates; u.v. detection, ethylacetate/hexane=1:3 in volume): 0.20.

Example 21

1-[5-Dimethylamino-3-methylsulfanyl-1-(2,4,6-trichloro-phenyl)-1H-pyrazol-4-yl-methyl]-naphthalen-2-ol and Dimethyl-[5-methylsulfanyl-4-(naphthalene-2-yloxy)methyl]-2-(2,4,6-trichloro-phenyl)-2H-pyrazol-3-yl]-amine

5 Utilizing the procedure of Example 4D, the mesylate of the compound of Example 1C (3 mmol) was prepared in situ in anhydrous methylene chloride (12 ml). Separately, sodium hydride (480 mg of 60% sodium hydride mineral oil dispersion, 288 mg, 12 mmol of sodium hydride) was added portionwise over several minutes to a stirred solution of 2-naphthol (1.73 g, 12 mmol) in anhydrous N,N-dimethylformamide (4
10 ml). After stirring at ambient temperature for 20 minutes, the sodium salt of the 2-naphthol/N,N-dimethylformamide mixture was added to the above-prepared mesylate/methylene chloride solution. The resulting mixture was stirred at 50°C for 18 hours. The solvents were removed in vacuo and the residue was extracted into ethylacetate/water (60 ml of each), with the pH adjusted to 6 (1N aqueous hydrochloric
15 acid). The separated aqueous phase was extracted with 60 ml of fresh ethyl acetate. The combined organic extracts were extracted with an equal volume of water, dried over anhydrous sodium sulfate and concentrated in vacuo to afford an amber oil (2.9 g). Flash chromatography of the entire sample (silica gel, 40 micron mesh; elution with ethylacetate/hexane=1:9 in volume) afforded the first title compound (the product of C-
20 alkylation; 388 mg) as a colorless foam, and the second title compound (the product of O-alkylation; 46 mg) as a colorless oil.

The first title compound (product of C-alkylation): ¹³C NMR (CDCl₃): 152.9, 149.1, 148.2, 136.5 (2), 135.1, 133.2, 129.4, 128.9, 128.6, 128.5, 126.1, 123.7, 123.0, 119.5, 118.0, 113.0, 42.7, 19.6, 16.0.

25 The second title compound (product of O-alkylation): ¹³C NMR (CDCl₃): 156.5, 153.4, 149.7, 136.1, 135.6, 134.6, 129.4, 129.1, 128.7, 127.7, 126.8, 126.4, 123.8, 119.3, 107.3, 107.0, 60.5, 42.6, 15.7.

Example 22

Dimethyl-(5-methylsulfanyl-4-phenoxy)methyl-2-(2,4,6-trichloro-phenyl)-2H-pyrazol-3-yl]-amine and 2-[5-Dimethylamino-3-methylsulfanyl-1-(2,4,6-trichloro-phenyl)-1H-pyrazol-4-ylmethyl]-phenol

30

To a solution of phenol (564 mg, 6.0 mmol) in anhydrous N,N-dimethylformamide (1.0 ml), sodium hydride (240 mg of 60% sodium hydride mineral

oil dispersion; 144 mg, 6.0 mmol of sodium hydride) was added portionwise over 5 minutes. The mixture was then stirred for 15 minutes at ambient temperature. Separately-utilizing the general procedure of Example 4D, the mesylate of the compound of Example 1C (1.5 mmol) was prepared in situ in anhydrous methylene chloride (6 ml). The entire phenol sodium salt/N,N-dimethylformamide sample was added all at once to the above-prepared (well-stirred/ice-bath-chilled) mesylate solution: and the resulting mixture was heated at 50°C for 18 hours. The solvent was removed in vacuo and the resulting residue was extracted into ethylacetate/water (60 ml of each) with the pH of the aqueous phase adjusted to 6.0 (1N hydrochloric acid). The separated aqueous phase was twice extracted with 30 ml portions of fresh ethyl acetate. The organic extracts were combined, extracted with an equal volume of water, dried over anhydrous sodium sulfate, and concentrated in vacuo to a solid (900 mg). Flash chromatography (silica gel, 40 micron mesh; elution with ethylacetate/hexane=1:9 in volume) of the entire sample afforded an impure sample (90 mg) of the C-alkylated title compound, and a likewise partially-purified sample (190 mg) of O-alkylated title compound. Final purification of both compounds by separate silica gel flash chromatography of each sample (elution with hexane/methylene chloride=2:3 in volume) afforded 11 mg and 58 mg respectively, of the C-alkylated title compound and the O-alkylated title compound.

The second title compound (product of C-alkylation): ^{13}C NMR (CDCl_3): 154.4, 149.4, 149.0, 136.4, 136.1, 135.0, 130.2, 128.8, 127.8, 126.1, 120.3, 116.1, 111.2, 42.7, 24.2, 15.2.

The first title compound (product of O-alkylation): ^{13}C NMR (CDCl_3): 158.6, 153.1, 149.5, 136.1, 135.6, 134.5, 129.5, 128.7, 121.0, 115.1, 107.2, 60.4, 42.6, 15.7.

Example 23

[4-(2-Methoxy-naphthalen-1-ylmethyl)-5-methylsulfanyl-2-(2,4,6-trichloro-phenyl)-2H-pyrazol-3-yl]-dimethyl-amine

To a well-stirred solution of the first title compound of Example 21 (121 mg, 0.25 mmol) in anhydrous tetrahydrofuran (1.0 ml), sodium hydride (25 mg of 60% sodium hydride mineral oil dispersion; 15 mg, 0.63 mmol of sodium hydride) was added portionwise over 5 minutes. After stirring the mixture for 10 minutes at ambient temperature, methyl iodide (78 μl , 1.25 mmol) was added. The reaction mixture was stirred 1 hour (ambient temperature) before a second portion of methyl iodide (78 μl ,

-37-

1.25 mmol) was added. The reaction was stirred for 18 hours at ambient temperature before in vacuo removal of solvent. The residue was extracted into ethylacetate/water (60 ml of each). The separated aqueous extract was extracted twice with 30 ml portions of fresh ethyl acetate. The combined organic extracts were dried over
5 anhydrous sodium sulfate and concentrated in vacuo to afford a yellow oil (138 mg). Flash chromatography, using the entire sample (silica gel, 40 micron mesh; elution with ethyl acetate/hexane=1:9 in volume) afforded the title compound (74 mg) as a colorless amorphous solid.

¹³C NMR (CDCl₃): 154.9, 149.9, 148.4, 136.3 (2), 135.3, 133.5, 129.3, 128.5,
10 128.4, 128.3, 125.9, 124.2, 123.3, 121.1, 113.5, 112.7, 56.5, 41.7, 19.8, 15.2.

Example 24

[4-(2-Isopropoxy-naphthalen-1-ylmethyl)-5-methylsulfanyl-2-(2,4,6-trichloro-phenyl)-2H-pyrazol-3-yl]-dimethyl-amine

To a well-stirred solution of the first title compound of Example 21 (120 mg, 0.24
15 mmol) in anhydrous tetrahydrofuran (1.0 ml), sodium hydride (29 mg of 60% sodium hydride mineral oil dispersion; 17.4 mg, 0.73 mmol of sodium hydride) was added portionwise over 5 minutes. After stirring the mixture at ambient temperature for 30 minutes, 2-iodopropane (192 μ l, 1.92 mmol) was added; and the resulting mixture was stirred (ambient temperature) for 18 hours. TLC inspection of a reaction aliquot
20 indicated incomplete reaction. A second portion of 2-iodopropane (200 μ l, 2.0 mmol) was added, and the mixture was stirred for an additional 18 hours. The solvent was removed in vacuo and the residue was extracted into ethyl acetate/water (60 ml of each). The separated aqueous layer was extracted twice with 20 ml portions of fresh ethyl acetate. The combined organic extracts were dried over anhydrous sodium
25 sulfate and concentrated in vacuo to afford a yellow oil (161 mg). Flash chromatography (silica gel, 40 micron mesh; elution with ethyl acetate/hexane=5:95 in volume) afforded the title compound (70 mg) as a colorless foam.

¹³C NMR (CDCl₃): 153.4, 150.0, 148.4, 136.3 (2), 135.2, 133.8, 129.4, 128.4, 128.2, 128.1, 125.7, 124.5, 123.3, 116.2, 112.8, 71.6, 41.6, 22.6, 20.1, 15.3.

Example 25

4-[5-Dimethylamino-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-yl-methyl]-4H-isoquinoline-1,3-dione

To a well-stirred suspension of homophthalimide (467 mg, 2.9 mmol) in anhydrous N,N-dimethylformamide (1.8 ml), sodium hydride (128 mg of 60% sodium hydride mineral oil dispersion, 76.8 mg, 3.2 mmol of sodium hydride) was added all at once. The resulting mixture was heated at 65°C for 20 minutes. Utilizing the method of Example 4D, the compound of Example 1C (1.9 mmol) was prepared in situ. With both mixtures chilled to 5°C, the entire sodium homophthalimide N,N-dimethylformamide sample and mesylate solution were combined. Acetonitrile (5 ml) was added, and the mixture was heated for 18 hours at 65°C. The solvents were removed in vacuo to afford a solid which was extracted into methylene chloride/water (100 ml of each), with the pH adjusted to 9.0. The separated organic phase was extracted with an equal volume of dilute aqueous sodium carbonate (pH 9); and then extracted with an equal volume of water. Anhydrous sodium sulfate drying and concentration in vacuo afforded a foam (909 mg). Crystallization of the entire sample from isopropyl alcohol (30 ml) afforded 140 mg (14.4% yield) of the title compound (colorless crystals, m.p. 186-187°C).

Example 26

2-[5-Dimethylamino-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-ylmethyl]-isoindole-1,3-dione

To a well-stirred ice-bath-chilled solution of phthalimide (427 mg, 2.9 mmol) in anhydrous N,N-dimethylformamide (4 ml), sodium hydride (128 mg of 60% sodium hydride mineral oil dispersion, 77 mg, 3.2 mmol of sodium hydride) was added. The resulting mixture was stirred at ambient temperature for 20 minutes. Separately, to an ice-bath-chilled solution of the compound of Example 1C (700 mg, 1.9 mmol) and triethylamine (304 μ l, 2.2 mmol) in anhydrous methylene chloride (9 ml), methanesulfonyl chloride (104 μ l, 2.1 mmol) was added all at once; and the resulting mixture was stirred (5°C) for 15 minutes to complete the in situ formation of the mesylate of the compound of Example 1C. While stirring the freshly prepared mesylate solution (5°C), the entire sodium phthalimide/N,N-dimethylformamide mixture (also chilled to 5°C), was added all at once; and the resulting reaction mixture was gently refluxed for 18 hours. The solvent was removed in vacuo, and the residue was

extracted into methylene chloride/dilute aqueous sodium bicarbonate (pH 8; 100 ml of each). The separated organic phase was dried over magnesium sulfate and concentrated in vacuo to an oil (762 mg). Flash chromatography with the entire sample (30 g silica gel, 40 micron mesh; elution with ethyl acetate/hexane in volume ratios of 6:94, 8:92, 12:88, and 1:4, respectively for each of four successively-collected 250 ml volumes of eluent) afforded the title compound (160 mg), as a colorless amorphous solid.

^{13}C NMR (CDCl_3): 167.8, 151.7, 148.6, 136.3, 135.6, 134.7, 133.9, 132.1, 128.6, 123.3, 106.4, 42.5, 31.9, 15.0.

10

Example 27

A. 5-Amino-1-(2,6-dichloro-4-trifluoromethyl-phenyl)-3-ethyl-1H-pyrazole-4-carboxylic acid methyl ether

A solution consisting of 2-cyano-3-ethyl-3-ethoxy-acrylic acid methyl ester (20.14 g, 109 mmol) and 2,6-dichloro-4-trifluoromethylphenylhydrazine (26.93 g, 109 mmol) in glacial acetic acid (42 ml) was heated at reflux for 4 hours; and then allowed to stir at ambient temperature for 18 hours. The solvent was removed in vacuo and the residual oil was extracted into 150 ml of ethyl acetate. Residual acetic was removed from the extract by mixing with aqueous saturated sodium bicarbonate. The separated ethyl acetate extract was dried (anhydrous sodium sulfate and concentrated in vacuo to a brown oil (47 g). Flash chromatography of the entire sample (silica gel; 40 micron mesh; elution with ethylacetate/hexane = 15:85 in volume) afforded the title compound (19.5 g) as a waxy solid. TLC R_f (silica gel plates; u.v. detection; ethylacetate/hexane = 15:85 in volume): 0.30.

^{13}C NMR (CDCl_3): 165.2, 157.0, 151.5, 137.0, 127.5, 126.1 (2), 123.8, 120.4, 116.7, 93.2, 50.8, 22.1, 12.8.

B. 1-(2,6-Dichloro-4-trifluoromethyl-phenyl)-5-dimethylamino-3-ethyl-1H-pyrazole-4-carboxylic acid methyl ester

By the general method of Example 4B, utilizing 19.4 g (52 mmol) of the compound of Step A, the title compound was prepared and isolated as an orange oil (22.73 g). TLC R_f (silica gel plates; u.v. detection; ethylacetate/hexane = 15:85 in volume): 0.73.

^{13}C NMR (CDCl_3) 163.7, 158.6, 156.5, 136.3, 127.6, 125.8, 125.7, 124.0, 120.4, 116.8, 102.4, 51.0, 42.1, 22.7, 13.0.

C. [1-(2,6-Dichloro-4-trifluoromethylphenyl)-5-dimethylamino-3-ethyl-1H-pyrazol-4-yl]-methanol

To a dry ice-acetone bath chilled solution of the Step B compound (9.0 g, 22.6 mmol) in anhydrous tetrahydrofuran (80 ml), a 1.0M solution of diisobutylaluminum hydride (75 ml, 75 mmol of diisobutylaluminum hydride) was added dropwise over 5 minutes. The reaction was then stirred at 5°C (icebath) for 30 minutes. The reaction mixture was quenched by addition of water (4.5 ml) and stirred for 10 minutes prior to warming to about 50°C. The solvent was removed from the now heterogeneous (gelatinous) mixture in vacuo. The residue was pulped with ethyl acetate (100 ml), and the mixture filtered through celite. The filtrate solvent was removed in vacuo. The resulting residue was pulped with 40 ml of an ethylacetate/hexane (1:9 in volume) mixture, affording a colorless solid which was filtered and dried (5.1 g). Further purification of the entire sample by three successive pulpings in 20 ml of hexane (and product isolation by filtration) afforded the title compound (3.6 g) as a colorless solid. TLC R_f (silica gel plates; u.v. detection; ethylacetate/hexanes = 1:4 in volume): 0.40. ¹³C NMR (CDCl₃): 156.5, 152.1, 136.5, 127.7, 125.7 (2), 124.1, 120.5, 116.9, 106.7, 61.4, 43.1, 20.6, 13.4.

D. 8-[1-(2,6-Dichloro-4-trifluoromethylphenyl)-5-dimethylamino-3-ethyl-1H-pyrazol-4-ylmethyl]-quinolin-7-ol

By the general method of Example 21, and utilizing 7-hydroxyquinoline (237 mg, 1.63 mmol) in place of 2-naphthol as the nucleophilic reactant and the in situ formed mesylate of the Step C compound as the substrate, the title compound (the product of C-alkylation, 208 mg) was prepared and isolated as a light yellow amorphous solid. TLC R_f (silica gel plates; u.v. detection, ethylacetate/hexane = 1:4 in volume): 0.36. HRMS m/z 509.10872 (M+1, C₂₄H₂₂N₄OCl₂F₃).

Example 28

Enantiomeric {2-[1-(2,6-Dichloro-4-trifluoromethylphenyl)-5-dimethylamino-3-ethyl-1H-pyrazol-4ylmethyl]-1,2,3,4-tetrahydro-isoquinolin-3yl}-methanol

By the general method of Example 4D, and utilizing (+)-3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline as the nucleophilic reactant and the compound of Example 27C (762 mg, 2.0 mmol) as the substrate, the title compound was prepared and isolated as an amorphous solid (190 mg). TLC R_f (silica gel plates; u.v. detection; ethylacetate/hexane=1.4 in volume): 0.16.

^{13}C NMR (CDCl_3) 156.5, 151.4, 136.7, 136.6, 133.6, 133.3, 129.0, 127.8, 126.9, 126.5, 126.0, 125.7, 125.6, 124.2, 120.5, 117.0, 107.2, 61.9, 58.2, 47.8, 45.7, 42.6, 26.6, 20.7, 13.2.

Example 29

5 A. 5-Amino-3-ethyl-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carboxylic acid methyl ester

By the general method of Example 27A, 2-cyano-3-ethyl-3-ethoxy-acrylic acid methyl ester (145 g, 0.79 mol) was reacted with 2,4,6-trichlorophenylhydrazine (167 g, 0.79 mol) to afford (following flash chromatography on 40 micron mesh silica gel; elution with ethylacetate/hexane=1:4 in volume) the title compound as an orange oil (176 g). TLC R_f (silica gel plates, u.v. detection; ethylacetate/hexane=1.4 in volume): 0.43.

^1H NMR (CDCl_3): 7.43 (2H, s), 5.14 (2H, broad s), 3.78 (3H, s), 2.74 (2H, q, $J=7.6$ Hz), 1.20 (3H, t, $J=7.6$ Hz).

15 B. 5-Dimethylamino-3-ethyl-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carboxylic acid methyl ester

By the general method of Example 4B, utilizing the Step A compound (4.64 g, 1.3 mmol), the title compound (2.9 g) was prepared and isolated as an orange solid. TLC R_f (silica gel plates; u.v. detection; ethylacetate/hexane=1:10 in volume): 0.42.

20 ^1H NMR (CDCl_3): 7.44 (2H, s), 3.84 (3H, s), 2.84 (2H, q, $J=7.6$ Hz), 2.70 (6H, s), 1.23 (3H, t, $J=7.6$ Hz).

 C. [5-Dimethylamino-3-ethyl-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-yl]-methanol

By the general method of Example 27C and utilizing the Step B compound of this Example (1.50 g, 4.0 mmol), the title compound was prepared and isolated as a colorless waxy solid (320 mg). TLC R_f (silica gel plates; u.v. detection; ethylacetate/hexane=1:4 in volume): 0.16.

^1H NMR (CDCl_3) 7.36 (2H, s), 4.50 (2H, m), 2.65 (6H, s), 2.58 (2H, q, $J=7.6$ Hz), 1.21 (3H, t, $J=7.6$ Hz).

30 D. Enantiomeric {2-[5-Dimethylamino-3-ethyl-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-ylmethyl]-1,2,3,4-tetrahydroisoquinolin-3-yl}-methanol

By the general method of Example 4D and utilizing the dextrorotatory enantiomer (+)-3-hydroxy-1,2,3,4-tetrahydroisoquinoline (240 mg, 1.4 mmol) as the

-42-

nucleophilic reactant and the in situ formed mesylate of the Step C compound as the substrate, the title compound was prepared and isolated as a light yellow oil [12 mg of pure material following flash chromatography (silica gel; 40 micron mesh; elution with ethylacetate/hexane=1:6 in volume) of the crude product].

5 ¹³C NMR (CDCl₃) 155.5, 151.9, 135.3, 134.9, 134.1, 133.5, 128.9, 128.6, 126.7, 126.2, 109.3, 86.8, 71.6, 58.2, 50.6, 43.1, 31.3, 20.5, 13.8. HRMS m/z 493.1345 (M+1, C₂₄H₂₈N₄OCl₃).

Example 30

10 [2-(2,6-Dichloro-4-trifluoromethylphenyl)-4-(3-ethoxymethyl-3,4-dihydro-1H-isoquinolin-2-ylmethyl)-5-methylsulfanyl-2H-pyrazol-3-yl]-dimethylamine, dihydrochloride salt


To an ambient temperature solution of the free base form of the title compound of this Example (38 mg) in anhydrous hydrochloric acid/diethyl ether (0.5 ml), 5 drops of a saturated anhydrous hydrochloric acid/diethyl ether solution were added.
15 Immediately, a white crystalline salt (the title compound) formed which was filtered and dried in vacuo (35 mg, m.p. 75.0-75.3°C).

Example 31

The following compounds were prepared according to the method of the Example listed in Table 1.



-43-





Table 1





15	Z	NMR Data	Method of Example
	Benzyloxy	¹³ C NMR (CDCl ₃): 152.9, 149.9, 138.3, 136.1, 135.5, 134.6, 128.7, 128.4, 128.0, 127.6, 108.2, 72.0, 61.9, 42.7, 15.3.	22
20		¹³ C NMR (CDCl ₃): 152.7, 149.9, 137.6, 136.9, 136.1, 135.4, 134.7, 129.7, 128.9, 128.7, 127.4, 125.6, 108.7, 74.5, 60.1, 42.8, 29.2, 27.9, 18.9, 15.4.	22
25	3-Hexyloxy	¹ H NMR (CDCl ₃): 0.88 (1H, m), 1.08 (8H, m), 1.26 (2H, m), 2.48 (3H, s), 2.52 (3H, m), 2.67 (6H, s), 2.69 (2H, m), 3.46 (3H, m), 7.45 (2H, s).	22
30	N(C ₂ H ₅) ₂ (4-trifluoromethyl rather than 4-chloro)	¹ H NMR (CDCl ₃): 1.04 (6H, t), 2.47 (3H, s), 2.52 (4H, q), 2.66 (6H, s), 3.43 (2H, s), 7.68 (2H, s).	10
35	Cyclopropylamino	¹³ C NMR (CDCl ₃): 151.5, 148.9, 136.2, 135.3, 134.7, 128.6, 110.6, 43.0, 42.2, 30.0, 15.0, 6.5	7

-44-

	Z	NMR Data	Method of Example
5	Cyclopentylamino	^{13}C NMR (CDCl_3): 151.5, 148.8, 136.2, 135.3, 134.7, 128.6, 110.8, 59.4, 42.9, 41.6, 33.2, 24.1, 15.1	7
10	(3-Methoxyphenyl)-2-aminoethyl	^1H NMR (CDCl_3): 2.02 (1H, broad s), 2.50 (3H, s), 2.66 (6H, s), 3.72 (2H, s), 3.82 (3H, s), 3.85 (2H, s), 6.80 (1H, m), 6.96 (2H, overlapping multiplets), 7.75 (1H, m), 7.44 (2H, s).	7
15	 (4-trifluoromethyl rather than 4-chloro)	^1H NMR (CDCl_3): 2.52 (3H, s), 2.65 (6H, s), 2.76 (2H, m), 2.90 (2H, m), 3.55 (2H, s), 3.68 (2H, s), 7.0-7.19 (4H, m), 7.71 (2H, s).	10
20	$\text{N}(\text{C}_2\text{H}_5)_2$	^{13}C NMR (CDCl_3): 151.8, 149.7, 136.2, 135.2, 134.8, 128.6, 109.8, 47.1, 46.0, 42.4, 15.1, 11.5.	7
25		^{13}C NMR (CDCl_3): 152.3, 149.7, 136.1, 135.3, 135.2, 134.7, 128.6, 126.5, 126.0, 125.5, 108.5, 55.7, 51.4, 49.8, 42.4, 29.5, 15.2. ^1H NMR (CDCl_3): 2.50 (3H, s), 2.64 (6H, s), 2.75 (2H, m), 2.90 (2H, m), 3.54 (2H, s), 3.67 (2H, s), 7.0-7.17 (4H, m), 7.45 (2H, s).	7
30	2-Cyclopropylmethyleneamino	^1H NMR (CDCl_3): 0.12 (2H, m), 0.46 (2H, m), 0.97 (1H, m), 1.67 (1H, broad s), 2.46 (3H, s), 2.66 (6H, s), 3.68 (2H, s), 7.41 (2H, s).	7

	Z	NMR Data	Method of Example
5		¹³ C NMR (CDCl ₃): 152.3, 149.6, 147.4, 147.1, 136.1, 135.3, 134.7, 128.6, 127.0, 126.5, 111.4, 109.5, 108.5, 55.9, 55.9, 55.3, 53.5, 51.4, 50.0, 42.4, 29.1, 15.1.	7
10		¹ H NMR (CDCl ₃): 1.9 (2H, m), 2.40 (3H, s), 2.46 (6H, s), 2.66 (2H, t), 3.22 (2H, t), 3.70 (2H, s), 6.4 (1H, m), 6.6-6.8 (3H, m), 7.17 (1H, s), 7.36 (1H, s).	7
15		¹³ C NMR (CDCl ₃): 151.7, 149.1, 139.3, 137.5, 136.2, 135.4, 134.8, 129.2, 129.0, 128.6, 126.7, 125.8, 110.7, 55.3, 43.0, 40.7, 29.5, 28.0, 18.9, 15.2.	7
20		¹³ C NMR (CDCl ₃): 157.7, 149.5, 136.4, 135.2, 135.0, 128.6, 111.7, 54.3, 45.1, 42.4, 32.6, 18.9, 18.8, 15.1.	7
25	(p-chlorobenzyl)- (3-propanol)amino	¹³ C NMR (CDCl ₃): 151.8, 149.9, 137.1, 136.2, 135.6, 135.0, 133.0, 131.0, 128.7, 128.4, 107.5, 63.1, 58.2, 52.6, 48.1, 42.3, 28.6, 14.7.	7
30	(m-chlorobenzyl)- (3-propanol)amino	¹³ C NMR (CDCl ₃): 151.8, 149.9, 140.9, 136.2, 135.5, 134.8, 134.1, 129.6, 129.5, 128.7, 127.6, 127.3, 107.6, 62.9, 58.3, 52.4, 48.1, 42.3, 28.8, 14.7.	7
35	(m-methoxybenzyl)- (3-propanol)amino	¹³ C NMR (CDCl ₃): 159.6, 151.8, 150.0, 140.3, 136.2, 135.5, 134.9, 129.2, 128.6, 121.9, 114.8, 113.0, 107.8, 63.0, 59.0, 55.2, 52.5, 48.1, 42.3, 28.7, 14.7.	7


	Z	NMR Data	Method of Example
5	(p-methylbenzyl)-(3-propanol)amino	¹³ C NMR (CDCl ₃): 151.8, 150.1, 136.8, 136.2, 136.1, 135.5, 135.3, 134.9, 129.7, 128.9, 128.6, 107.7, 63.3, 58.7, 52.6, 48.1, 42.2, 28.6, 21.1, 14.7.	7
10	(p-nitrobenzyl)-(3-propanol)amino	¹³ C NMR (CDCl ₃): 151.8, 149.7, 147.1, 147.07, 136.1, 135.6, 134.7, 130.0, 129.8, 128.7, 123.5, 107.6, 62.4, 58.2, 52.4, 48.4, 42.5, 29.0, 14.5.	7
15		¹³ C NMR (CDCl ₃): 151.6, 149.2, 136.3, 136.2, 135.3, 128.6, 110.8, 63.7, 51.6, 47.1, 42.5, 38.4, 29.8, 28.6, 25.7, 24.9, 21.4, 15.1.	7
20	benzylmethylamino	¹³ C NMR (CDCl ₃): 152.0, 149.9, 139.5, 136.2, 135.3, 134.8, 129.2, 128.6, 128.2, 126.9, 109.1, 62.2, 51.3, 42.6, 41.3, 15.0.	7
25	benzyl(2-hydroxyethyl)amino	¹³ C NMR (CDCl ₃): 151.7, 149.4, 138.8, 136.2, 135.5, 134.8, 129.5, 129.0, 128.6, 128.3, 128.2, 127.2, 108.7, 59.0, 58.9, 55.0, 47.9, 42.9, 14.5.	7
30		¹³ C NMR (CDCl ₃): 152.0, 149.7, 136.1, 135.3, 134.9, 134.8, 134.6, 133.9, 129.1, 128.6, 126.5, 126.1, 125.5, 116.7 (2), 109.2, 72.2, 69.4, 56.2, 50.4, 47.8, 42.4, 30.8, 15.2.	13

Example 32

The following compounds were prepared according to the coupling method of Example 4D, followed by the alkylation according to the method of Example 15 for those compounds of Table 2 wherein R' is not hydrogen, and they were derived from

the dextrorotary enantiomer (+)-3-substituted-1,2,3,4-tetrahydroisoquinoline prepared by the general method of Preparation 2 hereafter. The pyrazole starting material was prepared by the method of the Example listed in Table 2.

Table 2




R'	R''	XR ₃	NMR or HRMS	Method of Example
CF ₃	CH ₃	C ₂ H ₅	HRMS m/z 541.1710 (M+1, C ₂₆ H ₃₀ N ₄ OCl ₂ F ₃)	27C
Cl	CH ₃	C ₂ H ₅	¹³ C NMR (δ, CDCl ₃) ppm 156.1, 151.6, 136.2, 135.0, 134.6, 133.9, 129.1, 128.5 (2), 126.5, 126.1, 125.6, 107.5, 72.3, 58.9, 56.3, 50.3, 47.1, 42.6, 30.4, 20.7, 13.5.	29C
CF ₃	C ₂ H ₅	C ₂ H ₅	HRMS m/z 554.1853 (M, C ₂₇ H ₃₁ N ₄ OCl ₂ F ₃)	27C
Cl	H	C ₃ H ₇	¹³ C NMR (δ, CDCl ₃) ppm 154.8 151.5, 136.4, 135.4, 133.6, 133.2, 129.0, 128.6, 127.0, 126.5, 126.1, 107.5, 62.1, 58.0, 47.5, 45.5, 42.6, 29.3, 26.0, 22.2, 13.7.	29C

Example 33

The following compounds were prepared according to the methods of the Examples listed in Table 3.

-48-

Table 3




R'	R'''	XR ₃	NMR or HRMS	Method of Example
Cl	CH ₂	SCH ₃	HRMS m/z 545.08672 (M, C ₂₇ H ₂₆ Cl ₃ N ₃ OS)	21, 23
Cl	C ₂ H ₅	OCH ₃	¹³ C NMR (δ, CDCl ₃) ppm 162.5, 153.9, 150.2, 136.9, 135.2, 134.9, 133.5, 129.4, 128.4, 128.2, 127.9, 125.7, 124.4, 123.1, 122.5, 114.8, 98.9, 65.0, 55.4, 41.6, 17.8, 15.2.	5D, 21, 23
Cl	CH ₂ CH=CH ₂	SCH ₃	¹³ C NMR (δ, CDCl ₃) ppm 153.9, 149.9, 148.4, 136.3, 135.3, 135.2, 133.9, 133.6, 129.5, 128.5, 128.3, 125.9, 124.4, 123.4, 121.7, 117.3, 114.8, 112.7, 70.4, 41.7, 19.9, 15.2.	21, 23

5	Cl	C ₂ H ₅	SCH ₃	¹³ C NMR (δ, CDCl ₃) ppm 154.2, 149.9, 148.4, 136.3, 135.2, 135.1, 133.6, 129.3, 128.4, 128.2, 125.8, 124.4, 123.2, 121.4, 114.5, 112.8, 64.9, 41.6, 19.9, 15.3, 15.2.	21, 23
10	Cl	CH(CH ₃) ₂	SCH ₃	¹³ C NMR (δ, CDCl ₃) ppm 154.2, 149.9, 148.4, 136.3, 135.2, 135.1, 133.7, 129.3, 128.4, 128.2, 125.8, 124.4, 123.1, 121.2, 114.3, 112.8, 75.7, 41.5, 28.8, 19.8, 19.5, 15.2.	21, 23
15	Cl	H	C ₂ H ₅	HRMS m/z 473.0651 (M, C ₂₄ H ₂₂ Cl ₃ N ₃ O)	29C, 21
20	Cl	C ₂ H ₅	C ₂ H ₅	¹³ C NMR (δ, CDCl ₃) ppm 155.0, 154.0, 149.2, 136.5, 136.0, 135.1, 133.6, 129.3, 128.4, 128.3, 128.1, 125.8, 124.2, 123.2, 121.5, 114.2, 110.6, 64.7, 42.1, 20.9, 19.5, 15.3, 13.0.	29C, 21, 23
25	Cl	H (6-methoxy substituted)	SCH ₃	¹³ C NMR (δ, CDCl ₃) ppm 155.6, 151.2, 149.0, 148.1, 136.5, 136.4, 135.2, 130.4, 128.8, 128.5, 127.2, 125.3, 120.0, 118.7, 118.4, 113.1, 106.9, 55.3, 42.7, 19.8, 16.0.	21
30	CF ₃	H	C ₂ H ₅	HRMS m/z 508.12123 (M+1, C ₂₅ H ₂₃ N ₃ OCl ₂ F ₃)	27C, 21
35	CF ₃	C ₂ H ₅	C ₂ H ₅	HRMS m/z 536.15083 (M+1, C ₂₇ H ₂₇ N ₃ OCl ₂ F ₃)	27C, 21, 23

Example 34

The following compounds were prepared according to the method of Example 23. The starting compounds of use in this method were prepared by the method of Example 21.

Table 4



R'	R'''	XR ₃	H	K	NMR (CDCl ₃) ppm
Cl	CH ₃	SCH ₃	N	CH	¹³ C NMR: 154.9, 150.0, 148.1, 147.4, 143.7, 142.2, 136.2, 135.5, 135.0, 133.1, 129.3, 128.5, 121.1, 120.6, 116.8, 112.0, 56.5, 41.6, 19.5, 15.1.
CF ₃	CH ₃	C ₂ H ₅	CH	N	¹ H NMR: 8.96 (1H, m), 8.19 (1H, m), 7.79 (1H, m), 7.66 (2H, s), 7.3-7.42 (2H, two overlapping multiplets), 4.63 (3H, s), 3.87 (6H, s), 2.24 (2H, q, J=7.5 Hz), 0.92 (3H, t, J=7.5 Hz)
Cl	CH ₃	SCH ₃	CH	N	¹³ C NMR: 158.4, 150.0, 149.6, 148.9, 147.6, 146.0, 136.3, 135.1, 128.4, 127.3, 124.0, 123.5, 118.7, 114.4, 113.4, 56.3, 42.4, 18.9, 15.5.

-51-

5	CF ₃	C ₂ H ₅	C ₂ H ₅	CH	N	¹³ C NMR: 155.8, 149.4, 149.0, 140.0, 136.8, 132.6, 132.0, 128.0, 127.4, 125.5, 125.4, 124.3, 123.5, 120.8, 118.4, 115.2, 111.0, 64.6, 42.5, 21.0, 18.9, 14.9, 12.9.
---	-----------------	-------------------------------	-------------------------------	----	---	--

Example 35

10 A. 2-{1-[1-(2,6-Dichloro-4-trifluoromethylphenyl)-5-dimethylamino-3-ethyl-1H-pyrazol-4-ylmethyl]-naphthalen-2-yloxy}-ethanol tert-butyl-dimethylsilyl ether

To a well-stirred solution of 1-[1-(2,6-Dichloro-4-trifluoromethylphenyl)-5-dimethylamino-3-ethyl-1H-pyrazol-4-ylmethyl]-naphthalen-2-ol (130 mg, 0.26 mmol) (listed in Table 3) in tetrahydrofuran (1.0 ml), sodium hydride (31 mg of 60% sodium hydride mineral oil dispersion; 19 mg, 0.78 mmol of sodium hydride) was added portionwise over five minutes; and five minutes thereafter 744 mg (2.6 mmol) of 1-iodo-2-(tert-butyl-
15 dimethylsilyloxy)ethane was added before heating the mixture for 18 hours at 45-50°C. TLC examination showed incomplete reaction. Twice more, 744 mg (2.6 mmol) additions of 1-iodo-2-(tert-butyl-dimethylsilyloxy)ethane were made, each time followed by heating the reaction at 50°C for 18 hours. After removing solvent in vacuo, the
20 residue was extracted with ethyl acetate/water (100 ml of each). The separated organic extract was dried (anhydrous sodium sulfate) and concentrated in vacuo to an oil. Flash chromatography (silica gel, 40 micron mesh; elution with ethyl acetate/hexane 5:95 in volume) afforded the title compound as an oil (53 mg). ¹H NMR (CDCl₃): 0.07 (6H, s), 0.88 (9H, s), 0.92 (3H, t, J=7.5 Hz), 2.24 (2H, q, J=7.5 Hz), 2.42 (6H, s), 3.96
25 (2H, t), 4.15 (2H, t), 7.16-7.32 (3H, m), 7.58 (2H, s), 7.64-7.75 (2H, m), 7.8-7.88 (1H, m).

B. 2-{1-[1-(2,6-Dichloro-4-trifluoromethylphenyl)-5-dimethylamino-3-ethyl-1H-pyrazol-4-ylmethyl]-naphthalen-2-yloxy}-ethanol

A solution of the compound of step A (50 mg, 0.075 mmol) and tetrabutylammonium fluoride (150 μl of a 1.00 M tetrahydrofurane solution, 0.15 mol)
30 in tetrahydrofuran (0.25 ml) was stirred at ambient temperature for 2 hours. The entire sample was dissolved in ethyl acetate/water (50 ml of each). The separated organic extract was then extracted twice with equal volumes of water, dried (anhydrous sodium sulfate), and concentrated in vacuo to an oil (50 mg). Flash chromatography of the entire sample (silica gel, 40 micron mesh; elution with ethyl acetate/hexane = 3:7 in
35 volume) afforded the title compound (27 mg) as an amorphous solid.

TLC R_f (silica gel plates, u.v. detection, ethyl acetate/water = 3:7 in volume): 0.34; ^1H NMR (CDCl_3): 1.00 (3H, t, $J=7.5$ Hz), 2.12 (1H, broad m), 2.34 (2H, q, $J=7.5$ Hz), 2.47 (6H, s), 3.95-4.08 (2H, m), 4.24 (2H, t), 4.33 (2H, s), 7.25-7.46 (3H, m), 7.68 (2H, s), 7.75-7.94 (2H, m), 8.00 (1H, m).

5

Example 36

2-{8-[1-(2,6-Dichloro-4-trifluoromethyl-phenyl)-5-dimethylamino-3-ethyl-1H-pyrazol-4-ylmethyl]-quinolin-7-yloxy}-ethanol

By the method of Example 35, the compound of Example 27D (200 mg, 0.39 mmol) was converted into the title compound (36 mg, isolated as an amorphous solid).

10 $^1\text{HNMR}(\text{CDCl}_3)$: 0.96 (3H, t), 2.02 (1H, broad), 2.34 (6H, s), 3.86 (2H, m), 4.13 (2H, t), 4.61 (2H, s), 7.14-7.42 (2H, overlapping multiplets), 7.61 (2H, s), 7.71 (1H, d), 8.08 (1H, dd), 8.88 (1H, m).

The following Preparations illustrate the preparation of intermediates.

Preparation 1

15 Racemic(1,2,3,4-Tetrahydro-isoquinolin-3-yl)-methanol [also referred to as(±)-3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline]

To a well stirred, ice-bath-chilled slurry of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride (75 g, 0.351 mol. Aldrich Chemical Co.) in anhydrous methanol (600 ml), sodium methoxide (37.92 g, 0.702 mol) was added in small solid
20 portions over a 10 minute period. After 30 minutes of brisk stirring, the methanol was removed and the colorless residue was dried in vacuo overnight. The entire sample was stirred in anhydrous tetrahydrofuran causing the organic portion to dissolve completely. A 1.0 M solution of lithium aluminum hydride in tetrahydrofuran (351 ml, 0.351 mol) was added in a rapid stream to the well-stirred mixture over a 20 minute
25 period (mild exotherm). The reaction mixture was then vigorously refluxed for 2 hours. At 5°C, the reaction was quenched by cautious addition of 15% aqueous sodium hydroxide. The mixture was filtered, and the filtrate was concentrated in vacuo to a yellow solid. The entire sample was then dissolved in methylene chloride (400 ml) and filtered to remove residual inorganic salts. Solvent removal in vacuo afforded the title
30 compound as an orange solid (47.01 g, 70% yield). TLC R_f (silica gel plates, u.v. detection, methanol/methylene chloride=5:95 in volume): 0.46; ^{13}C NMR (CDCl_3): 135.4, 134.1, 129.3, 126.3, 126.1, 125.9, 65.4, 55.0, 47.8, 30.9.

Preparation 2

Dextrorotatory enantiomer of (1,2,3,4-Tetrahydro-isoquinolin-3-yl)-methanol
(also referred to as (+)-3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline)

To a solution of (+)-3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline (Preparation
5 1; 47.01 g, 0.288 mol) in isopropyl alcohol (159 ml), a solution of (S)-(+)-mandelic acid
-(43.81 g, 0.288 mol) in isopropyl alcohol (159 ml) was added. The resulting solution
was allowed to stand at ambient temperature for 48 hours, during which time a heavy
orange crystalline mass formed. The isolated crystalline solid (13.06 g) was dissolved
in hot isopropyl alcohol (63 ml). After standing for 1 hour at ambient temperature, the
10 newly-formed crystalline solid was isolated by filtration (8.2 g, m.p. 138°C). The
recrystallization procedure was repeated twice more, using 63 ml and 60 ml volumes
of isopropyl alcohol to afford 7.08 g and 6.76 g of crystalline material, respectively. (In
each case, the crystallization was allowed to proceed for 2 hours at ambient
temperature prior to filtration.) A 138-139°C m.p. was observed after the final
15 crystallization. The entire sample was dissolved in methylene chloride water (300 ml
and 100 ml, respectively) with the pH adjusted to 9.5 (potassium carbonate). The
phases were separated, and the aqueous portion was extracted with three 50 ml
portions of fresh methylene chloride. The combined organic extracts were dried
(anhydrous sodium sulfate) and concentrated in vacuo to afford the optically resolved
20 title compound as a colorless amorphous solid (2.02 g, 8.6% yield). $[\alpha]^{20}_D + 103^\circ$
($c=1.83$, CH_2Cl_2); ^{13}C NMR (CDCl_3): identical to that of the racemic compound
prepared in Preparation 1.

Preparation 3

Levorotatory enantiomer of (1,2,3,4-Tetrahydro-isoquinolin-3-yl)-methanol [also
25 referred to as (-)-3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline]


Substituting (R)-(-)-mandelic acid for (S)-(+)-mandelic acid in the Preparation 2
procedure (and utilizing 17.9 g of the alcohol-amine prepared in Preparation 1), the
levorotatory title compound (0.65 g, 7.3% yield) was obtained as a colorless amorphous
solid. $[\alpha]^{20}_D - 100.4^\circ$ (CH_2Cl_2 , $c=1.43$); ^1H NMR and ^{13}C NMR (CDCl_3): identical in all
30 respects to those observed for the racemic (Preparation 1) and dextrorotatory
(Preparation 2) products.

-54-

CLAIMS

1. A compound of the formula

5



- 10 and the pharmaceutically acceptable acid addition salts thereof,
wherein

A is CH₂;

X₁ is a covalent bond, CH₂, NR, wherein R is hydrogen linear C₁-C₈ alkyl or
branched C₃-C₈ alkyl, O, or S;

- 15 R₁, R₂ and R₃ are each independently linear C₁-C₈ alkyl, branched C₃-C₈ alkyl,
C₃-C₈ alkenyl wherein the double bond is not adjacent to the N or X₁ when X₁ is oxygen
or sulfur, or C₃-C₇ cycloalkyl (CH₂)_n wherein n is 0, 1, 2, 3 or 4; or R₁ and R₂ when
taken together with the nitrogen form a saturated four, five or six membered ring
optionally condensed with benzo; and R₃ may also be (CH₂)_qQ₁R₁₉ wherein q is 0, 1 or
20 2, Q₁ is O, S, NH, N(C₁-C₈ alkyl) or a covalent bond when X₁ is not a covalent bond,
and R₁₉ is hydrogen, linear C₁-C₈ alkyl, branched C₃-C₈, C₃-C₈ alkenyl, or C₃-C₆
cycloalkyl (CH₂)_n wherein n is 0 to 4;

- Y is phenyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl,
imidazolyl, benzimidazolyl, furanyl, benzofuranyl, thiazolyl, benzothiazolyl, isothiazolyl,
25 benzisothiazolyl, isoxazolyl, benzisoxazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl,
azaindolyl, oxazolyl, benzoxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, or piperidinyl,
each of which may be substituted by one to three of any one of fluoro, chloro, bromo,
or methyl, or one of trifluoromethyl; with the proviso that Y is not unsubstituted phenyl;
and


30

-55-

Z is

(a)

5



10

wherein the B ring is phenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, thienyl, or indolyl, each of which may be substituted by methyl, methoxy, fluoro, chloro, bromo or iodo; or a saturated 5- or 6-membered carbocyclic ring or a partially unsaturated ring having one or two double bonds;

15

R_4 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, or hydroxy, fluoro, chloro, bromo, iodo, or trifluoromethyl;

R_5 is hydrogen, linear C_1 - C_6 alkyl, branched C_3 - C_8 alkyl, C_3 - C_8 alkenyl, or $(CH_2)_o$ - X_2 -(CH_2) $_r$ - Q_2 - R_6 ;

20

R_6 is hydrogen, linear C_1 - C_6 alkyl, branched C_3 - C_8 alkyl, or C_3 - C_8 alkenyl;

X_2 and Q_2 are each independently O, S, NH, N(C_1 - C_6 alkyl), or one of X_2 and Q_2 may be a covalent bond;

m is 0 or 1;

o is 1 or 2;


25

p is 1 or 2;

r is 0, 1, or 2;

(b)

30




-56-

wherein R_4 and R_5 are as defined above, and t and u are each independently 1 or 2;


- (c) $-NR_7R_8$ wherein R_7 and R_8 are each independently hydrogen, C_1 - C_8 linear alkyl, branched C_3 - C_8 alkyl, C_3 - C_8 alkenyl, $(CH_2)_vCH_2OH$, $(CH_2)_vNR_9R_{10}$, wherein v is 0 to 3, and R_9 and R_{10} are each independently hydrogen, or linear C_1 - C_8 alkyl; C_1 - C_{12} cycloalkyl, (C_3 - C_{12} cycloalkyl) $(CH_2)_n$, (C_6 - C_{10} bicycloalkyl) $(CH_2)_n$, wherein n is 0 to 4, benzofused C_3 - C_6 cycloalkyl, C_1 - C_6 hydroxyalkyl, phenyl, phenyl (C_1 - C_3 alkylene), each of which may be substituted by one or two of hydroxy, fluoro, chloro, bromo, C_1 - C_5 alkyl, or C_1 - C_5 alkoxy; or R_7 and R_8 may be taken together with the nitrogen to form a saturated or partially unsaturated 5- to 7-membered ring which may contain one of O, S, NH or N(C_1 - C_6 alkyl) and which may be substituted by C_1 - C_6 alkyl, hydroxy or phenyl wherein any double bond(s) are not adjacent to any heteroatoms;

(d)



wherein B , R_4 and R_5 are as defined above, w , x , y and z are each independently 1 or 2, and W is $(CH_2)_q$ wherein q is as defined above, N(C_1 - C_6 alkyl), or oxygen;

(e)




-57-

wherein B, R₄, m and p are as defined above;

(f)

5




10 wherein B and R₄ are as defined above;

(g) O(CH₂)_vR₁₁

wherein v is 0 to 3 and R₁₁ is linear C₁-C₈ alkyl, branched C₃-C₈ alkyl, phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, benzimidazolyl, furanyl, benzofuranyl, thiazolyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, isoxazolyl, benzisoxazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, oxazolyl, benzoxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, piperidinyl, or thienyl, each of which may be substituted by one or two of any one of fluoro, chloro, bromo, methyl, or trifluoromethyl;

(h)


20



25 wherein A is defined above and is linked to position 1 or 2 while R₁₄ is attached to position 2 or 1, respectively; F, G, H, I, J and K are independently C or N, provided that not more than three of H, I, J and K are N with not more than two adjacent nitrogens; R₁₂ and R₁₃ each independently are hydrogen, linear C₁-C₆ alkyl, branched C₃-C₈ alkyl, C₃-C₈ alkenyl, fluoro, chloro, bromo, trifluoromethyl, hydroxy, thiol, C₁-C₁₂ alkoxy, C₁-C₁₂ thioalkanyl, C₃-C₁₂ alkenoxy or C₃-C₁₂ thioalkenyl wherein the double bond is not adjacent to the oxygen or sulfur, and R₁₄ is hydroxy, C₁-C₁₂ alkoxy, C₃-C₁₂ alkenoxy wherein the double bond is not adjacent to the oxygen, or -X₂-(CH₂)_rQ₂R₆ wherein X₂, r, Q₂ and R₆ are as defined above in paragraph (a) except that Q₂ is not sulfur, or R₁₄

30

- is $\text{NR}_{15}\text{R}_{16}$ wherein R_{15} and R_{16} are each independently hydrogen, linear $\text{C}_1\text{-C}_8$ alkyl, branched $\text{C}_3\text{-C}_8$ alkyl, $\text{C}_3\text{-C}_8$ alkenyl wherein the double bond is not adjacent to the nitrogen, or $\text{C}_3\text{-C}_7$ cycloalkyl- $(\text{CH}_2)_n$ wherein n is as defined above, or R_{15} and R_{16} together with the nitrogen form a saturated five or six membered ring optionally
 5 condensed with benzo; or
 (i)




10

- wherein D,E,F and G are independently C or N, provided that not more than two of D,E,F and G are N, and R_{12} and R_{14} are as defined in paragraph (h), A, defined above, is linked to a carbon in formula XV; and R_{14} is linked to a carbon located adjacent to
 15 the carbon to which A is linked.

2. A compound according to claim 1 wherein Y is 2,4,6-tri-substituted phenyl.
3. A compound according to claim 2 wherein Y is 2,4,6-trichlorophenyl, 2,6-dichloro-4-trifluoromethylphenyl or 2,6-dibromo-4-fluorophenyl.
- 20 4. A compound according to claim 1 or 2 wherein $\text{X}_1\text{-R}_3$ is ethyl or methylthio.
5. A compound according to any one of claims 1 to 4 wherein R_1 and R_2 are each methyl.
6. A compound according to any one of claims 1 to 5 wherein Z is NR_7R_8
 25 wherein R_7 is phenyl or phenyl substituted by one of fluoro, chloro, nitro, methyl or methoxy.
7. A compound according to claim 6 wherein R_8 is $\text{CH}_2\text{CH}_2\text{CH}_2\text{OH}$, $\text{CH}_2\text{CH}_2\text{OH}$, or methyl.
8. A compound according to any one of claims 1 to 5 wherein Z is 1,2,3,4-
 30 tetrahydroisoquinolin-2-yl and R_5 is $(\text{CH}_2)_6\text{-X}_2\text{-(CH}_2)_r\text{-Q}_2\text{-R}_6$.
9. A compound according to claim 8 wherein R_5 is $(\text{CH}_2)_k\text{OH}$ wherein k is 1 to 4, or $\text{CH}_2\text{OCH}_2\text{CH}_2\text{OR}_6$.

10. A compound according to any one of claim 1 to 5 wherein Z is 1, 2, 3, 4-tetrahydroisoquinolin-2-yl, wherein R_5 is substituted at position 3, and the absolute configuration at the 3-position is S or R or R,S.

11. A compound according to any one of claims 1 to 5 wherein Z is of the
5 formula




10 with the absolute configuration at position 3 determined by its derivation from (+)-3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline, wherein R_{19} is methyl, ethyl, isopropyl, cyclopropylmethylene, or hydroxyethylene.

12. A compound according to any one of claims 1 to 5 wherein Z is as defined in (h).

15 13. A compound according to claim 12 wherein A is linked to position 1, R_{14} is at position 2 and is $X_2 - (CH_2)_i Q_2 R_6$.

14. A compound according to claim 13 wherein F, G, H, I, and J, are each carbon, K is carbon or nitrogen, and R_{14} is 2-methoxy, 2-ethoxy, 2-isopropoxy, or 2-cyclopropylmethoxy.

20 15. A compound according to any one of claims 1 to 5 wherein Z is



25


wherein K is C or N and R_{20} is methyl, ethyl, isopropyl, cyclopropylmethylene, or hydroxyethylene.

16. A compound according to any one of claims 1 to 5 wherein Z is as defined in (a), B is phenyl, p and m are each 1, and R_5 is CH_2OCH_3 .

30 17. A compound according to any one of claims 1 to 5 wherein Z is

-60-

5




wherein B is phenyl, m is 0, and p is 1.

- 10 18. A compound according to claim 1 wherein said compound is
 2-{1-[1-(2,6-dichloro-4-trifluoromethylphenyl)-5-dimethylamino-3-ethyl-1H-pyrazol-4-ylmethyl]-naphthalen-2-yloxy}-ethanol;
 enantiomeric [4-(3-methoxymethyl-3,4-dihydro-1H-isoquinolin-2-ylmethyl)-5-methylsulfanyl-2-(2,4,6-trichlorophenyl)-2H-pyrazol-3-yl]-dimethylamine derived from (+)-
 15 3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline;
 enantiomeric [2-(2,6-dichloro-4-trifluoromethylphenyl)-4-(3-ethoxymethyl-3,4-dihydro-1H-isoquinolin-2-ylmethyl)-5-ethyl-2H-pyrazol-3-yl]-dimethylamine derived from
 (+)-3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline;
 [2-(2,6-dichloro-4-trifluoromethylphenyl)-5-ethyl-4-(7-methoxyquinolin-8-ylmethyl)-
 20 2H-pyrazol-3-yl]-dimethylamine;
 [2-(2,6-dichloro-4-trifluoromethylphenyl)-4-(2-ethoxy-naphthalen-1-ylmethyl)-5-ethyl-2H-pyrazol-3-yl]-dimethylamine;
 [4-(2-ethoxynaphthalen-1-ylmethyl)-5-ethyl-2-(2,4,6-trichlorophenyl)-2H-pyrazol-3-yl]-dimethylamine;
 25 [4-(7-methoxyquinolin-8-ylmethyl)-5-methylsulfanyl-2-(2,4,6-trichlorophenyl)-2H-pyrazol-3-yl]-dimethylamine;
 2-{1-[5-dimethylamino-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-ylmethyl]-naphthalen-2-yloxy}-ethanol;
 enantiomeric [2-(2,6-dichloro-4-trifluoromethylphenyl)-5-ethyl-4-(3-methoxymethyl-3,4-dihydro-1H-isoquinolin-2-ylmethyl)-2H-pyrazol-3-yl]-dimethylamine
 30 derived from (+)-3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline;
 [4-(2-cyclopropylmethoxynaphthalen-1-ylmethyl)-5-methylsulfanyl-2-(2,4,6-trichlorophenyl)-2H-pyrazol-3-yl]-dimethylamine.

-61-

19. A composition for the treatment of (a) illnesses induced or facilitated by corticotropin releasing factor or (b) inflammatory disorders, stress and anxiety related disorders, including stress-induced depression and headache, abdominal bowel syndrome, immune suppression, HIV infections, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, hemorrhagic stress, drug and alcohol withdrawal symptoms, drug addiction, and fertility problems, which comprises a compound of the formula I as defined in claim 1 and a pharmaceutically acceptable carrier.

20. A compound of the formula



15

wherein R' is CH₂OH or C(O)O(C₁-C₃ alkyl), R₁, R₂ and R₃ are each independently linear C₁-C₆ alkyl, branched C₃-C₈ alkyl, C₃-C₈ alkenyl wherein the double bond is not adjacent to the N or X₁ when X₁ is oxygen or sulfur, C₃-C₇ cycloalkyl (CH₂)_n wherein n is 0, 1, 2, 3 or 4; or R₁ and R₂ when taken together with the nitrogen form a saturated four, five or six membered ring optionally condensed with benzo;

X₁ is a covalent bond, CH₂NR, wherein R is hydrogen or linear C₁-C₆ alkyl, O, or S; and

Y is phenyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, benzimidazolyl, furanyl, benzofuranyl, thiazolyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, isoxazolyl, benzisoxazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, oxazolyl, benzoxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, or piperidinyl, each of which may be substituted by one to three of any one of fluoro, chloro, bromo, or methyl, or one of trifluoromethyl; with the proviso that Y is not unsubstituted phenyl.

21. A method for the treatment of (a) illnesses induced or facilitated by corticotropin releasing factor, or (b) stress and anxiety related disorders, including stress-induced depression and headache, abdominal bowel syndrome, inflammatory disorders, immune suppression, HIV infections, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, hemorrhagic stress, drug and alcohol withdrawal

-62-

symptoms, drug addiction, and fertility problems, particularly depression, which comprises administering to a subject in need of such treatment a compound of formula I as defined in claim 1.

A. CLASSIFICATION OF SUBJECT MATTER

IPC 5 C07D231/44 A61K31/415 A61K31/47 C07D401/06 C07D231/38
C07D231/52 C07D403/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US,A,5 063 245 (M.E. ABREU ET AL.) 5 November 1991 cited in the application see the entire document; in particular columns 11-12, table I, entry 15 -----	1-21

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
 "&" document member of the same patent family

Date of the actual completion of the international search

2 March 1994

Date of mailing of the international search report

- 9. 03. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentiaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Fink, D

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 93/10716

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 21 is directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 93/10716

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-5063245	05-11-91	NONE	
<hr/>			